CA2591121A1 - Ventricular pacing - Google Patents
Ventricular pacing Download PDFInfo
- Publication number
- CA2591121A1 CA2591121A1 CA002591121A CA2591121A CA2591121A1 CA 2591121 A1 CA2591121 A1 CA 2591121A1 CA 002591121 A CA002591121 A CA 002591121A CA 2591121 A CA2591121 A CA 2591121A CA 2591121 A1 CA2591121 A1 CA 2591121A1
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- electrodes
- pacing
- component
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002861 ventricular Effects 0.000 title description 9
- 210000005240 left ventricle Anatomy 0.000 claims abstract description 58
- 210000005241 right ventricle Anatomy 0.000 claims abstract description 52
- 210000002216 heart Anatomy 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000008602 contraction Effects 0.000 claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 210000002837 heart atrium Anatomy 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 6
- 230000001360 synchronised effect Effects 0.000 claims description 3
- 210000005245 right atrium Anatomy 0.000 description 18
- 210000003748 coronary sinus Anatomy 0.000 description 15
- 230000005684 electric field Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 239000004020 conductor Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 210000001186 vagus nerve Anatomy 0.000 description 6
- 210000002620 vena cava superior Anatomy 0.000 description 6
- 206010006580 Bundle branch block left Diseases 0.000 description 5
- 206010006578 Bundle-Branch Block Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 201000001715 left bundle branch hemiblock Diseases 0.000 description 5
- 210000003742 purkinje fiber Anatomy 0.000 description 5
- 230000001746 atrial effect Effects 0.000 description 4
- 230000005672 electromagnetic field Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000001992 atrioventricular node Anatomy 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 239000003990 capacitor Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003989 dielectric material Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 210000001174 endocardium Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000591 tricuspid valve Anatomy 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 210000004375 bundle of his Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000003105 phrenic nerve Anatomy 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000033986 Device capturing issue Diseases 0.000 description 1
- 244000290594 Ficus sycomorus Species 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001862 defibrillatory effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005244 lower chamber Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000005243 upper chamber Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/371—Capture, i.e. successful stimulation
Abstract
A method and apparatus are disclosed for treating a condition of a patient's heart includes placing a first electrode and a second electrode in a right ventricle of the heart. A reference electrode is placed within the patient and internal or external to the heart. A pacing signal is generated including a first signal component, a second signal component and a reference component with the first and second signal components having opposite polarity and with both of the first and second components having a potential relative to the reference component. The first component is transmitted to the first electrode. The second component is transmitted to the second electrode. The reference electrode is connected to the reference component which may be an electrical ground. The pacing signal and the placement of the electrodes are selected to alter a contraction of a left ventricle of the heart.
Description
VENTRICULAR PACING
I.
CROSS REFERENCE TO RELATED APPLICATION
This application is being filed as a PCT International Patent Application on December 2005, in the name of Action Medical, Inc., a U.S. national corporation, applicant for the designation of all countries except the U.S. and Daniel Felipe Ortega and Alberto German Giniger, both citizens or Argentina, and Qingsheng Zhu and J.
Edward Shapland, citizens of the U.S.; applicants for the designatiort of the U.S. only, and claims priority to Argentine Application Serial No. P 040104782, filed 20 December 2004.
II.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to ventricular pacing. More particularly, this invention pertains to synchronous pacing of a patient's left ventricle by electrodes residing in the patient's right ventricle.
I.
CROSS REFERENCE TO RELATED APPLICATION
This application is being filed as a PCT International Patent Application on December 2005, in the name of Action Medical, Inc., a U.S. national corporation, applicant for the designation of all countries except the U.S. and Daniel Felipe Ortega and Alberto German Giniger, both citizens or Argentina, and Qingsheng Zhu and J.
Edward Shapland, citizens of the U.S.; applicants for the designatiort of the U.S. only, and claims priority to Argentine Application Serial No. P 040104782, filed 20 December 2004.
II.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to ventricular pacing. More particularly, this invention pertains to synchronous pacing of a patient's left ventricle by electrodes residing in the patient's right ventricle.
2. Description of the Prior Art a. Pacing For Brad c~ ardia Percutaneously placed pacing electrodes are commonly positioned only in the right-side chambers (right atrium or right ventricle) of the heart. Access to such chambers is readily available. Such access is through the superior vena cavity into the right atrium and then into the right ventricle.
Electrode placement into the left ventricle is normally avoided. Access is not as direct as in right ventricle placement. More important, emboli risk in the left ventricle is greater than in the right ventricle. Emboli which might develop in the left ventricle by reason of the electrode placement have direct access to the brain via the aorta from the left ventricle. This presents a significant risk of stroke.
Historically, pacing electrodes were placed only in the right ventricle to treat bradycardia (slow heart rate). Right atrium pacing was less understood and was more complex.
With advances in electro-physiology, pacing of both the right atrium and right ventricle was developed. Such dual chamber pacing resulted in better hemodynamic output than right ventricle-only pacing.
In additional to treating bradycardia, dual chamber pacing maintained synchrony between the chambers. Recent clinical evidence suggests that conventional ventricular pacing from the right ventricle creates asynchronous contraction of the left ventricle, leading to inefficient mechanical contraction and reduced hemodynamic performance.
Long term right ventricular pacing has even been found to be associated with an increased risk of developing or worsening heart failure.
At first, combined pacing of the right ventricle and right atrium was performed by advancing two electrode leads through the superior vena cava into the right atrium.
The first of these terminated at one or more electrodes which were attached to the endocardium of the atrium. The second lead (also having one or more electrodes) was advanced into the right ventricle with the electrode attached to the endocardium of the right ventricle.
Such historical dual chamber pacing was not without complications. The use of two leads resulting in a doubling of volume of the vasculature (e.g., the superior vena cava and jugular vein) occupied by such leads. Further, attachment of an electrode to the atrial wall was unreliable.
The historical problems of the dual chamber pacing led to the development of so-called "single pass" leads. Such leads have both the atrial and ventricle electrodes on a common lead.
An example of a single pass lead for pacing both the right ventricle and right atrial is taught in U.S. Patent. No. 6,230,061 B1 to Hartung issued May 8, 2001. The lead of the '061 patent is described as floating lead in that the lead and electrodes are not attached to the walls of the heart. In one embodiment of the '061 patent (Fig. 4a), two electrodes in the right atrium pace the right atrium. In a second embodiment (Fig.
4b), an electrode resides in the right ventricle to add right ventricular pacing. As will be described, the '061 patent describes an oppositely polarized electrode (which may be exposed on a subcutaneously placed implantable pulse generator).
It is Applicants' understanding the design of the '061 patent has not enjoyed great commercial success. Applicants believe this is due, at least in part, to the separate development of smaller profile leads and more reliable atrial attachment techniques.
Both of these developments address the problems of dual chamber pacing otherwise addressed by the '061 patent.
b. Pacing for Congestive Heart Failure Beginning in the 1990's, cardiac pacing has been considered for treatment of congestive heart failure (CHF). CHF patients suffer from low left ventricular output.
CHF is an extremely serious and progressive disease. While drug treatments exist, they may delay but do not stop or reverse the disease.
CHF patients face a progression of a debilitating condition which drastically alters lifestyle and will ultimately be fatal in the absence of heart transplant.
Unfortunately, many patients do not qualify for such transplants and the available number of donor hearts is inadequate to treat those who do qualify.
Many CHF patients have low left ventricular output due to a mismatch between contractile forces produced by muscles of the left ventricle free wall (the external wall of the left ventricle) and the opposing septum (the wall dividing the right and left ventricles). Ideally, the free wall and septum contract in synchrony during systole to urge blood through the aortic valve. When out of synchrony, the septal wall may be contracting while the free wall is relaxed. Instead of urging blood flow, at least a portion of the contractile energy of the septum is wasted.
The mismatch of free wall and septal contractility is believed to be due to disorders in the electrical conduction systems of the heart. This conduction system includes the A-V node, the Bundle of His and the Purkinje fibers.
Located at the upper end of the septum, the sinus node creates the synchronized neuraly-mediated signal for cardiac pacing. These signals are conducted by the specialized fibers comprising the A-V node and the Bundle of His (extending along the length of the septum) and further conducted to the muscle of the heart through the Purkinje fibers. The Purkinje fibers originate in the septum and extend through the apex of the heart and to the exterior walls of the heart including into and up the free wall of the left ventricle.
In a healthy heart, the signal flow from the A-V node to the free wall of the left ventricle is rapid to insure the free wall and septum contract in synchrony.
For example, a stimulating signal may flow to the free wall in about 70 - 90 milli-seconds.
In patients with conduction abnormalities, this timing may be significantly delayed (to 150 milli-seconds or more) resulting in asynchronous contraction.
In some patients, the conduction path through the Purkinje fibers may be blocked. The location of the block may be highly localized (as in the case of so-called "left bundle branch block" or LBBB) or may include an enlarged area of dysfunctional tissue (which can result from infaretion). In such cases, all or a portion of the free wall of the left ventricle is flaccid while the septum is contracting. In addition to contributing to asynchronous contraction, the contraction force of the free wall is weakened.
To address asynchronous contraction, CHF patients can be treated with cardiac pacing of the left ventricle. Such pacing includes applying a stimulus to the septal muscles in synchrony with stimulation applied to the muscles of the free wall of the left ventricle. While infracted tissue will not respond to such stimulus, non-infarcted tissue will contract thereby heightening the output of the left ventricle.
The prior art has developed various techniques for accomplishing left ventricle stimulation. For reasons noted above (i.e., emboli formation), endocardially positioned electrodes in the left ventricle are avoided. However, electrodes can be placed on the epicardial surface of the heart through surgical placement. The epicardial electrodes are positioned on the free wall of the left ventricle and are paced in synchrony with electrodes placed near the septum in the right ventricle.
Since epicardial electrodes require a surgical placement, the patient is subjected to two procedures - percutaneous placement of right ventricle electrodes (normally performed in a catheter lab by an electrophysiologist) and surgical placement of epicardial electrodes on the left ventricle (normally placed by a cardiac surgeon in a surgical suite). Also, such dual procedure is a burden on medical resources.
Percutaneous procedures have been developed for placement of an electrode to stimulate the free wall of the left ventricle. In such a procedure, an electrode lead is advanced through the coronary sinus. Part of the venous system, the coronary sinus extends from the right atrium and wraps around the heart on or near the epicardial surface and partially overlies the left ventricle free wall. In this percutaneous procedure, the electrode remains positioned in the coronary sinus overlying the left ventricle free wall with the lead passing through the coronary sinus and through the right atrium to the implantable pulse generator.
Unfortunately, a coronary sinus electrode is frequently less than optimal. The portion of the free wall most directly influenced by the electrode is the tissue directly underlying the coronary sinus at the location of the electrode. For many patients, this may not be the location of the free wall most in need of a stimulating therapy.
Accordingly, the resulting therapy is sub-optimal. Also, some patients may have an extremely small diameter coronary sinus or the coronary sinus may have such a tortuous shape that percutaneous positioning of an electrode within the coronary sinus is impossible or very difficult. Not uncommonly, advancing a lead from the right atrium into the coronary sinus is extremely time-consuming. Even if successful, such a procedure consumes significant health care resources (including precious catheter lab time). Finally, there are now up to three leads passing through and occupying the space of the superior vena cava (i.e., leads for the electrodes in the right ventricle, right atrium and the coronary sinus). U.S. patent application Publ. No. 2005/0125041 published June 9, 2005 shows (in Fig. 1) three leads passed through a superior vena cava with one lead residing in the right atrium, one in the right ventricle and one passed through the coronary sinus to overly the left ventricle.
Attempts at pacing the left ventricle by pacing stimulation in the right ventricle have been suggested. U.S. Pat. No. 6,643,546 B2 to Mathis et al. dated November 4, 2003 describes a lead with an array of electrodes along its length. The lead is placed in the right atrium and extending through the right ventricle, along the septal wall, and into the pulmonary artery. The concept requires that multiple electrodes from the array be pulsed simultaneously at significantly high voltages to produce an adequate electrical field to stimulate the LV septum. The current output from the pulse generator and battery will be very high due to the multiplicity of electrodes and high pacing voltages.
Such high output will cause a clinically unacceptable product lifespan. Since a large number of electrodes and supporting electronics are needed to implement such a therapy delivery mechanism, it is not known yet whether it is practically feasible, not least to mention that it is very complicated both in terms of device design/manufacturing as well clinical practice. No published reports known to this date have demonstrated the functional as well as clinical benefits for this multiple electrode stimulation approach in the ventricle.
As will be described with reference to a preferred embodiment, the present invention is directed to a left ventricle pacing system and method which does not require epicardial electrodes or electrodes in a coronary sinus. As will be described, the present invention includes electrodes in the right ventricle near the septal wall. These electrodes create a pulsed electrical field which stimulates both the septum and at least a portion of the free wall of the left ventricle. The present invention achieves these objectives without requiring excessive energy demands or power consumption.
III.
SUMMARY OF THE INVENTION
According to a preferred embodiment of the present invention, a method and apparatus are disclosed for treating a condition of a patient's heart. The method includes placing a first electrode and a second electrode in a right ventricle of the heart.
A reference electrode is placed within the patient and internal or external to the heart.
A pacing signal is generated including a first signal component, a second signal component and a reference component with the first and second signal components having opposite polarity and with both of the first and second components having a potential relative to the reference component. The first component is transmitted to the first electrode. The second component is transmitted to the second electrode.
The reference electrode is connected to the reference component which may be an electrical ground. The pacing signal and the placement of the electrodes are selected to alter a contraction of a left ventricle of the heart.
IV.
BRIEF DRESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic cross sectional view of the heart showing relevant anatomical features and schematically showing a catheter with pacing electrodes in the right ventricle and a subcutaneously placed implantable pulse generator;
FIG. 2 is the view of FIG. 1 showing electrodes in contact with a septal wall;
FIG. 2A is a cross-sectional view of an electrode lead showing a mechanism for attachment of an electrode to a septal wall;
FIG. 3 is the view of FIG. 1 showing an electrode lead formed, in part, from shape memory alloys for urging electrodes against a septal wall;
FIG. 4 is the view of FIG. 1 showing a further embodiment of an electrode lead for urging electrodes against a septal wall;
FIG. 5 is the view of FIG. 1 showing electrodes on a septal wall and energized by wireless transmission;
FIG. 6 is the view of FIG. 5 showing electrodes embedded within the septal wall;
FIG. 7 is the view of FIG. 4 showing the lead of FIG. 4 with multiple electrodes urged against the septal wall;
FIG. 7A is the view of FIG. 1 showing a conventional active fixation lead with a helix for attachment of the tip electrode to a septal wall;
FIG. 7B is the view of FIG. 1 showing a shocking electrode;
FIG. 8 is a view, taken in cross-section, of right and left ventricles of a heart showing the electrodes of FIG. 1 (without showing the lead body) energized to create electromagnetic fields;
FIG. 9 is the view of FIG. 8 showing the field shifted toward the left ventricle in response to repositioning of leads;
FIG. 10 is the view of FIG. 8 showing the field distorted toward a free wall of the left ventricle by influence of an external reference electrode;
Electrode placement into the left ventricle is normally avoided. Access is not as direct as in right ventricle placement. More important, emboli risk in the left ventricle is greater than in the right ventricle. Emboli which might develop in the left ventricle by reason of the electrode placement have direct access to the brain via the aorta from the left ventricle. This presents a significant risk of stroke.
Historically, pacing electrodes were placed only in the right ventricle to treat bradycardia (slow heart rate). Right atrium pacing was less understood and was more complex.
With advances in electro-physiology, pacing of both the right atrium and right ventricle was developed. Such dual chamber pacing resulted in better hemodynamic output than right ventricle-only pacing.
In additional to treating bradycardia, dual chamber pacing maintained synchrony between the chambers. Recent clinical evidence suggests that conventional ventricular pacing from the right ventricle creates asynchronous contraction of the left ventricle, leading to inefficient mechanical contraction and reduced hemodynamic performance.
Long term right ventricular pacing has even been found to be associated with an increased risk of developing or worsening heart failure.
At first, combined pacing of the right ventricle and right atrium was performed by advancing two electrode leads through the superior vena cava into the right atrium.
The first of these terminated at one or more electrodes which were attached to the endocardium of the atrium. The second lead (also having one or more electrodes) was advanced into the right ventricle with the electrode attached to the endocardium of the right ventricle.
Such historical dual chamber pacing was not without complications. The use of two leads resulting in a doubling of volume of the vasculature (e.g., the superior vena cava and jugular vein) occupied by such leads. Further, attachment of an electrode to the atrial wall was unreliable.
The historical problems of the dual chamber pacing led to the development of so-called "single pass" leads. Such leads have both the atrial and ventricle electrodes on a common lead.
An example of a single pass lead for pacing both the right ventricle and right atrial is taught in U.S. Patent. No. 6,230,061 B1 to Hartung issued May 8, 2001. The lead of the '061 patent is described as floating lead in that the lead and electrodes are not attached to the walls of the heart. In one embodiment of the '061 patent (Fig. 4a), two electrodes in the right atrium pace the right atrium. In a second embodiment (Fig.
4b), an electrode resides in the right ventricle to add right ventricular pacing. As will be described, the '061 patent describes an oppositely polarized electrode (which may be exposed on a subcutaneously placed implantable pulse generator).
It is Applicants' understanding the design of the '061 patent has not enjoyed great commercial success. Applicants believe this is due, at least in part, to the separate development of smaller profile leads and more reliable atrial attachment techniques.
Both of these developments address the problems of dual chamber pacing otherwise addressed by the '061 patent.
b. Pacing for Congestive Heart Failure Beginning in the 1990's, cardiac pacing has been considered for treatment of congestive heart failure (CHF). CHF patients suffer from low left ventricular output.
CHF is an extremely serious and progressive disease. While drug treatments exist, they may delay but do not stop or reverse the disease.
CHF patients face a progression of a debilitating condition which drastically alters lifestyle and will ultimately be fatal in the absence of heart transplant.
Unfortunately, many patients do not qualify for such transplants and the available number of donor hearts is inadequate to treat those who do qualify.
Many CHF patients have low left ventricular output due to a mismatch between contractile forces produced by muscles of the left ventricle free wall (the external wall of the left ventricle) and the opposing septum (the wall dividing the right and left ventricles). Ideally, the free wall and septum contract in synchrony during systole to urge blood through the aortic valve. When out of synchrony, the septal wall may be contracting while the free wall is relaxed. Instead of urging blood flow, at least a portion of the contractile energy of the septum is wasted.
The mismatch of free wall and septal contractility is believed to be due to disorders in the electrical conduction systems of the heart. This conduction system includes the A-V node, the Bundle of His and the Purkinje fibers.
Located at the upper end of the septum, the sinus node creates the synchronized neuraly-mediated signal for cardiac pacing. These signals are conducted by the specialized fibers comprising the A-V node and the Bundle of His (extending along the length of the septum) and further conducted to the muscle of the heart through the Purkinje fibers. The Purkinje fibers originate in the septum and extend through the apex of the heart and to the exterior walls of the heart including into and up the free wall of the left ventricle.
In a healthy heart, the signal flow from the A-V node to the free wall of the left ventricle is rapid to insure the free wall and septum contract in synchrony.
For example, a stimulating signal may flow to the free wall in about 70 - 90 milli-seconds.
In patients with conduction abnormalities, this timing may be significantly delayed (to 150 milli-seconds or more) resulting in asynchronous contraction.
In some patients, the conduction path through the Purkinje fibers may be blocked. The location of the block may be highly localized (as in the case of so-called "left bundle branch block" or LBBB) or may include an enlarged area of dysfunctional tissue (which can result from infaretion). In such cases, all or a portion of the free wall of the left ventricle is flaccid while the septum is contracting. In addition to contributing to asynchronous contraction, the contraction force of the free wall is weakened.
To address asynchronous contraction, CHF patients can be treated with cardiac pacing of the left ventricle. Such pacing includes applying a stimulus to the septal muscles in synchrony with stimulation applied to the muscles of the free wall of the left ventricle. While infracted tissue will not respond to such stimulus, non-infarcted tissue will contract thereby heightening the output of the left ventricle.
The prior art has developed various techniques for accomplishing left ventricle stimulation. For reasons noted above (i.e., emboli formation), endocardially positioned electrodes in the left ventricle are avoided. However, electrodes can be placed on the epicardial surface of the heart through surgical placement. The epicardial electrodes are positioned on the free wall of the left ventricle and are paced in synchrony with electrodes placed near the septum in the right ventricle.
Since epicardial electrodes require a surgical placement, the patient is subjected to two procedures - percutaneous placement of right ventricle electrodes (normally performed in a catheter lab by an electrophysiologist) and surgical placement of epicardial electrodes on the left ventricle (normally placed by a cardiac surgeon in a surgical suite). Also, such dual procedure is a burden on medical resources.
Percutaneous procedures have been developed for placement of an electrode to stimulate the free wall of the left ventricle. In such a procedure, an electrode lead is advanced through the coronary sinus. Part of the venous system, the coronary sinus extends from the right atrium and wraps around the heart on or near the epicardial surface and partially overlies the left ventricle free wall. In this percutaneous procedure, the electrode remains positioned in the coronary sinus overlying the left ventricle free wall with the lead passing through the coronary sinus and through the right atrium to the implantable pulse generator.
Unfortunately, a coronary sinus electrode is frequently less than optimal. The portion of the free wall most directly influenced by the electrode is the tissue directly underlying the coronary sinus at the location of the electrode. For many patients, this may not be the location of the free wall most in need of a stimulating therapy.
Accordingly, the resulting therapy is sub-optimal. Also, some patients may have an extremely small diameter coronary sinus or the coronary sinus may have such a tortuous shape that percutaneous positioning of an electrode within the coronary sinus is impossible or very difficult. Not uncommonly, advancing a lead from the right atrium into the coronary sinus is extremely time-consuming. Even if successful, such a procedure consumes significant health care resources (including precious catheter lab time). Finally, there are now up to three leads passing through and occupying the space of the superior vena cava (i.e., leads for the electrodes in the right ventricle, right atrium and the coronary sinus). U.S. patent application Publ. No. 2005/0125041 published June 9, 2005 shows (in Fig. 1) three leads passed through a superior vena cava with one lead residing in the right atrium, one in the right ventricle and one passed through the coronary sinus to overly the left ventricle.
Attempts at pacing the left ventricle by pacing stimulation in the right ventricle have been suggested. U.S. Pat. No. 6,643,546 B2 to Mathis et al. dated November 4, 2003 describes a lead with an array of electrodes along its length. The lead is placed in the right atrium and extending through the right ventricle, along the septal wall, and into the pulmonary artery. The concept requires that multiple electrodes from the array be pulsed simultaneously at significantly high voltages to produce an adequate electrical field to stimulate the LV septum. The current output from the pulse generator and battery will be very high due to the multiplicity of electrodes and high pacing voltages.
Such high output will cause a clinically unacceptable product lifespan. Since a large number of electrodes and supporting electronics are needed to implement such a therapy delivery mechanism, it is not known yet whether it is practically feasible, not least to mention that it is very complicated both in terms of device design/manufacturing as well clinical practice. No published reports known to this date have demonstrated the functional as well as clinical benefits for this multiple electrode stimulation approach in the ventricle.
As will be described with reference to a preferred embodiment, the present invention is directed to a left ventricle pacing system and method which does not require epicardial electrodes or electrodes in a coronary sinus. As will be described, the present invention includes electrodes in the right ventricle near the septal wall. These electrodes create a pulsed electrical field which stimulates both the septum and at least a portion of the free wall of the left ventricle. The present invention achieves these objectives without requiring excessive energy demands or power consumption.
III.
SUMMARY OF THE INVENTION
According to a preferred embodiment of the present invention, a method and apparatus are disclosed for treating a condition of a patient's heart. The method includes placing a first electrode and a second electrode in a right ventricle of the heart.
A reference electrode is placed within the patient and internal or external to the heart.
A pacing signal is generated including a first signal component, a second signal component and a reference component with the first and second signal components having opposite polarity and with both of the first and second components having a potential relative to the reference component. The first component is transmitted to the first electrode. The second component is transmitted to the second electrode.
The reference electrode is connected to the reference component which may be an electrical ground. The pacing signal and the placement of the electrodes are selected to alter a contraction of a left ventricle of the heart.
IV.
BRIEF DRESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic cross sectional view of the heart showing relevant anatomical features and schematically showing a catheter with pacing electrodes in the right ventricle and a subcutaneously placed implantable pulse generator;
FIG. 2 is the view of FIG. 1 showing electrodes in contact with a septal wall;
FIG. 2A is a cross-sectional view of an electrode lead showing a mechanism for attachment of an electrode to a septal wall;
FIG. 3 is the view of FIG. 1 showing an electrode lead formed, in part, from shape memory alloys for urging electrodes against a septal wall;
FIG. 4 is the view of FIG. 1 showing a further embodiment of an electrode lead for urging electrodes against a septal wall;
FIG. 5 is the view of FIG. 1 showing electrodes on a septal wall and energized by wireless transmission;
FIG. 6 is the view of FIG. 5 showing electrodes embedded within the septal wall;
FIG. 7 is the view of FIG. 4 showing the lead of FIG. 4 with multiple electrodes urged against the septal wall;
FIG. 7A is the view of FIG. 1 showing a conventional active fixation lead with a helix for attachment of the tip electrode to a septal wall;
FIG. 7B is the view of FIG. 1 showing a shocking electrode;
FIG. 8 is a view, taken in cross-section, of right and left ventricles of a heart showing the electrodes of FIG. 1 (without showing the lead body) energized to create electromagnetic fields;
FIG. 9 is the view of FIG. 8 showing the field shifted toward the left ventricle in response to repositioning of leads;
FIG. 10 is the view of FIG. 8 showing the field distorted toward a free wall of the left ventricle by influence of an external reference electrode;
FIG. 11 is the view of FIG. 9 with a reference electrode placed within the left ventricle;
FIG. 12 is the view of FIG. 14 with an external electrode placed on the epicardial surface of the heart;
FIG. 13 is a view with an external electrode placed within a coronary sinus;
FIG. 14 is the view of FIG. 9 with fields distorted to be biased toward the left ventricle by the addition of dielectric material on a side of the electrodes of FIG. 9;
FIG. 15 shows a field distorted towards an upper end of the free wall in response a reference electrode in a first position;
FIG. 16 is the view of FIG. 15 with a reference electrode switched to a second position:
FIG. 17 is the view of FIG. 15 with a reference electrode replaced by two polarized electrodes;
FIG. 18 is a graphical representation of pulsed waveforms to be applied by first and second electrodes of the various embodiments;
FIG. 18A is a view similar to that of FIG. 18 showing alternative waveforms;
FIG 18B is a view similar to FIG. 18 and showing two electrodes creating two separate fields to a reference electrode;
FIG. 19 is an electrical schematic for a portion of a pacing output desired in a pulse generator with programmable pacing configurations; and FIG. 20 is a side elevation view of a patient's head and neck showing application of the present invention to applying a pacing signal to a vagus nerve.
V.
DESCRIPTION OF A PREFERRED EMBODIMENT
Referring now to the various drawing figures, a description of the preferred embodiment of the present invention will now be provided. Incorporated herein by reference are the disclosures of U.S. Patent Nos. 6,230,061 B1 to Hartung issued May 8, 2001 and U.S. Patent No. 6,907,285 to Denker, et al., dated June 14, 2004;
U.S. patent application Publ. No. 2004/0153127 published August 5, 2004; U.S. Pat. No.
6,643,546 B2 to Mathis et al. dated November 4, 2003.
FIG. 12 is the view of FIG. 14 with an external electrode placed on the epicardial surface of the heart;
FIG. 13 is a view with an external electrode placed within a coronary sinus;
FIG. 14 is the view of FIG. 9 with fields distorted to be biased toward the left ventricle by the addition of dielectric material on a side of the electrodes of FIG. 9;
FIG. 15 shows a field distorted towards an upper end of the free wall in response a reference electrode in a first position;
FIG. 16 is the view of FIG. 15 with a reference electrode switched to a second position:
FIG. 17 is the view of FIG. 15 with a reference electrode replaced by two polarized electrodes;
FIG. 18 is a graphical representation of pulsed waveforms to be applied by first and second electrodes of the various embodiments;
FIG. 18A is a view similar to that of FIG. 18 showing alternative waveforms;
FIG 18B is a view similar to FIG. 18 and showing two electrodes creating two separate fields to a reference electrode;
FIG. 19 is an electrical schematic for a portion of a pacing output desired in a pulse generator with programmable pacing configurations; and FIG. 20 is a side elevation view of a patient's head and neck showing application of the present invention to applying a pacing signal to a vagus nerve.
V.
DESCRIPTION OF A PREFERRED EMBODIMENT
Referring now to the various drawing figures, a description of the preferred embodiment of the present invention will now be provided. Incorporated herein by reference are the disclosures of U.S. Patent Nos. 6,230,061 B1 to Hartung issued May 8, 2001 and U.S. Patent No. 6,907,285 to Denker, et al., dated June 14, 2004;
U.S. patent application Publ. No. 2004/0153127 published August 5, 2004; U.S. Pat. No.
6,643,546 B2 to Mathis et al. dated November 4, 2003.
A. Placement of an Electrode Pair in the Right Ventricle Generally speaking, the present invention is directed to creating a pulsed electrical field in the right ventricle with the field stimulating the musculature of the septum and free wall of the left ventricle to create coordinated contraction of the septum and free wall.
The present invention can be practiced with currently commercially available electrode leads and can also be enhanced with novel leads. FIG. 1 illustrates the invention in practice with such commercially available lead. As is the conventional usage for referencing relative direction, the terms "left" and "right" are used herein with reference to the patient's perspective. The terms "upper" and "lower" and similar terms such as "up" or "down" are used with reference to the base B of the heart being high and the apex A of the heart H being a lower end.
In FIG. 1, a patient's heart H is schematically shown in cross-section. The heart H includes the upper chambers of the right atrium RA and left atrium LA. The lower chambers are the right ventricle RV and left ventricle LV. Of the various venous vessels opening into the right atrium RA, only the superior vena cava SVC is shown.
Also, of the various heart valves, only the mitral valve MV (separating the left atrium LA from the left ventricle LV) and the tricuspid valve TV (separating the right atrium RA from the right ventricle RV) are shown. The septum S separates the right and left ventricles RV, LV and the free wall FW of the left ventricle LV is separately labeled.
The surface of the heart wall tissue opposing the chambers is the endocardium and is labeled as EN. The exterior surface of the heart is the epicardium and is labeled EP.
Not shown are coronary vessels of the heart or the pericardium surrounding the heart H.
In FIG. 1, an electrode lead is shown having a lead body LB1 and exposed electrodes El and E2. The first electrode E1 is positioned near the distal tip of the lead body LB1. The second electrode E2 is positioned more proximally on the lead body LB 1. . At the distal end, an attachment mechanism AM (such as a passive fixation design with tines or an active fixation design with a metallic helix) is shown for securing the first electrode E1 to the musculature of the heart H. The spacing of electrodes El, E2 could be greater than that of convention pacing electrodes permitting positioning of the first electrode E1 at the apex of the right ventricle RV
and the second electrode E2 in the right ventricle RV near the tricuspid valve TV. However, conventional leads with convention spacing have been used with the first or distal electrode attached to the septum (e.g., by a helix attachment HA) as shown in FIG. 7A.
The lead body LB1 is flexible and includes a bio-compatible, electrically insulating coating surrounding first and second conductors C1, C2 separately connected to the first and second electrodes E1, E2. In the various Figures, the lead bodies are broken at a line at the SVC to reveal the internal conductors C1, C2 extending to an implantable pulse generator IPG. In fact, the conductors C1, C2 are contained within the material of the lead body LB1 along their length. The term "implantable pulse generator IPG" is intended to include pacemakers, implantable converter defibrillators (ICD) and cardia resynchronization therapies (CRT), all known in the art.
The proximal end of the lead body terminates at a pin connector (not shown) as is customary. The pin connector has exposed electrical contacts uniquely connected to each of the conductors C1, C2. The pin connector may be releasably connected to the pulse generator IPG with the exposed contacts making electrical connection with unique contacts of the circuitry of the pulse generator IPG.
It will be appreciated that the prior art contains numerous examples of cardiac leads for placement in a chamber of the heart where the leads have, as described above, two or more electrodes spaced along a length of the lead, attachment mechanisms such as passive or active fixation and conductors and connector pins as described.
The current invention is not limited to pacing leads only, but rather is equally deployable with prior art ICD leads where it is customary to contain at least two electrodes in the RV. Such leads are selected of biocompatible material and treated (such as sterilized) for chronic placement in the patient.
The implantable pulse generator IPG is a small metallic container sealed for implantation in the patient and protecting internal circuitry. Commonly, such pulse generators are placed subcutaneously (e.g., in a dissected space between the skin and muscle layers of the patient). For cardiac pacing, such pulse generators are positioned in the upper chest on either the left or right front side of the patient near a shoulder.
However, placement need not be so restricted and such pulse generators could be placed in any convenient location selected by the physician.
Pulse generators contain internal circuitry for creating electrical impulses which are applied to the electrodes after the lead is connected to the pulse generator. Also, such circuitry may include sensing and amplification circuitry so that electrodes El, E2 may be used as sensing electrodes to sense and have the IPG report on the patient's electrophysiology.
The lead may be introduced to the vasculature through a small incision and advanced through the vasculature and into the right atrium RA and right ventricle to the position shown in FIG. 1. Such advancement typically occurs in an electrophysiology lab where the advancement of the lead can be visualized through fluoroscopy.
The pulse generator contains a battery as a power supply. With subcutaneous placement, replacement of a battery is well-known procedure. However, improvements in battery designs have resulted in longer-lasting batteries with the benefit of reducing the frequency of battery replacement. Alternatively, such batteries may be rechargeable in situ as is known in the art.
The pulse generator circuitry controls the parameters of the signals coupled to the electrodes E1, Ea. These parameters can include pulse amplitude, timing, pulse duration by way of example. The internal circuitry further includes circuit logic permitting reprogramming of the pulse generator to permit a physician to alter pacing parameters to suit the need of a particular patient. Such programming can be affected by inputting programming instructions to the pulse generator via wireless transmission from an external programmer. Pulse generators commonly include an exposed contact on the exterior of the generator housing. Such pulse generators may also be partially covered with an insulator such as silicone with a window formed in the silicone to expose a portion of the metallic housing which functions as a return electrode in so-called unipolar pacing. In conventional bipolar pacing, the window is not necessary.
Most commonly, the electrode is connected by the circuitry of the housing to an electrical ground. It will be appreciated that pulse generators as thus described are well known in the art and form no part of this invention per se.
While an implantable pulse generator is described in a preferred embodiment, the pulse generator may be external and coupled to the electrodes by percutaneous leads or wireless transmission. For example, a control of an implanted electrode is known for phrenic nerve stimulation and is described more fully in a product brochure "ATROSTIM PHRENIC NERVE STIMULATOR", AtroTech Oy, P.O. Box 28, FIN-33721, Tampere, Finland (June 2004). The Atrostim device sends signals from an external controller to an implanted antenna.
External pacing devices are typically used for providing temporary pacing therapy. The current invention is also believed to have advantages for this application as critically-ill patients requiring emergency, temporary pacing may also suffer further from asynchronous cardiac contraction associated with conventional RV pacing.
If desired, an external unit can be used to test a patient's suitability for the treatment.
Patient's who benefit from the therapy can then receive an implantable pulse generator for longer-term use.
B. Right Ventricle Electrodes Creating Left Ventricle-Stimulating Electrical Field FIGS. 1 and 8 illustrate commercially available leads and the associated electrical fields with both electrodes residing within the right ventricle with the distal electrode secured to the apex of the right ventricle. In FIG. 8, only the ventricles RV, LV are shown for ease of illustration. Also, for ease of illustration, FIG. 8 shows only the electrodes El, E2 without showing the remainder of the lead body LB 1.
While conventional bipolar leads are acceptable for use with the present invention, a wider spacing between electrodes E1, E2 can increase the field but can sacrifice some sensing capability. This trade-off can be mitigated by use of a three-electrode lead in the right ventricle RV. Such a lead would have a tip electrode and two ring electrodes, one located near the tip in the RV apex and one in the high part of the atrium, near the tricuspid valve. The sensing is performed between the tip and closer electrode. This will provide good so-called "near field" sensing and avoid so-called "far field" sensing of the atrium or skeletal muscles activity. The pacing could be between the ring electrodes to the return electrode located distally to the heart (as will be described). One could also combined the tip and nearest ring as one electrode to the return electrode and the other ring electrode to the return electrode at the opposite polarity.
The pulse generator IPG generates a first and a second pulsed waveform Wl, W2 applied, respectively, to the first and second electrodes E1, E2. FIG. 18 shows such waveforms Wi, W2. By way of example, and not intended to be limiting, the pulse duration PD is between about 0.1 to 2.0 milliseconds, the amplitude A may be 0.1 Volts to 10 or 20 Volts and the time delay TD between pulses is a targeting heart rate (e.g., 50 to 200 beats per minutes).
In FIG. 18, the pulses are shown as square waveforms but, in practice, can be any geometry. The first electrode El has positive charged pulses only. The second electrode E2 has negative charged pulses timed to coincide with the positive charged pulses of the positive electrode E1. While direct current (DC) pulses are preferred, the electrodes El, E2 could be energized with alternating current pulses with the signals to the electrodes El, E2 out of phase such that the positive pulses on the first electrode El coincide with negative pulses on the second electrode E2 and negative pulses on the first electrode El coincide with positive pulses on the second electrode E2.
With the electrodes El, EZ charged with opposite pulses, it is Applicants' current understanding that an electrical field is created between the electrodes E1, E2 with a field axis FA (FIG. 8) extending in a line between the electrodes EI, E2. In the absence of distorting influences (such as external magnetic fields, external electrodes or non-homogonous conductivity due to variances in conductivity of blood, tissue bone, etc.), the field is symmetrical about the field axis FA and is represented by field lines illustrated in the drawings as left field lines LFL to the left of the axis FA
(with left being from the patient's perspective) and right field lines RFL. The field lines represent the intensity of the electrical field. The intensity diminishes rapidly as a function of the distance from the field axis FA.
In the embodiment of FIG. 1, in order for the fields generated by the electrodes EI, E2 to have a significant influence on both the septal walls and the free wall FW of the left ventricle LV, a voltage potential across the electrodes must be substantially high. However, such high voltages are not practical in a pacing electrode and are more normally associated with defibrillating treatments. Also, such voltages would cause an extremely significant drain on a battery requiring impractical frequency of battery replacement.
C. Improving Field Influence on Left Ventricle FIG. 9 illustrates benefits associated with movement of the electrodes El, E2 from the interior of the right ventricle RV (FIGS. 1 and 8) to direct placement of the electrodes E1, E2 on the septal wall S. Such movement shifts the field lines toward both the septal wall S and the free wall FW of the left ventricle LV. However, it is believed that even with such improvement, voltages required for effective stimulation of the septal wall and the free wall of the left ventricle would be impractically high.
The present invention utilizes a reference electrode RE in combination with the electrodes E1, E2 in the right ventricle to result in effective pacing of the left ventricle LV. Although the physics and physiology of the mechanism of action are not fully understood, it is presently believed that the reference electrode RE distorts the electromagnetic field otherwise created between the right ventricle electrodes E1, Ez to urge an intensity of the electromagnetic field deeper into the septal wall S
of the left ventricle LV. It is believed this occurs by creating a third high current density spot (or spots) away from the two electrodes in the wall and towards the reference electrode at the point where the current flows between the electrode El and the reference electrode RE and between the electrode E2 and the reference electrode RE coincide in space and time. This is illustrated in FIG. 10. Such a phenomenon is believed to facilitate the activation of the surviving conduction fibers in the Left Bundle Branch Block (LBBB) patients and Purkinje fibers and create a more rapid and uniform activation of the left ventricle LV that follows a similar pattern to the normal activation present in patients without LBBB.
The reference electrode may be physically attached to the housing of the implantable pulse generator IPG (and thereby having a neutral charge). Such an electrode RE is shown in FIGS. 1 - 7B. It will be appreciated that the reference electrode RE can be connected to the implantable pulse generator IPG by a conductor.
The reference electrode could be another common electrode that exists in the conventional pacing or ICD system, such as an electrode in the atrium or a defibrillation coil electrode situated in the SVC, RA or RV.
As shown in FIG. 10, the consequence of the reference electrode RE is presently believed to have a deforming effect on the electromagnetic field generated between the first and second electrodes El, E2. This is illustrated in FIG. 10 by distorting the left field lines LFL toward the septal wall S and free wall FW of the left ventricle LV.
Also, the right field lined RFL are compressed toward the axis FA to alter the field from the symmetric presentation of FIGS. 8 and 9 to the asymmetric presentation of FIG. 10 with the field biased toward the septal wall S and the free wall FW of the left ventricle LV.
It has been found that within energy levels associated with available implantable pulse generators (up to 10 or 20 volts) effective activation of the left ventricle LV can be achieved with the pacing arrangement of FIG 7A, where the first electrode El is attached to the mid- or upper-septum. In such arrangement, the reference electrode RE
is on the housing of the generator IPG and positioned subcutaneously near the right or left shoulder. The re-direction of the field as described, the inventors believe, may also be useful in decreasing defibrillation thresholds if arrangement similar to FIG. 7B is used. In FIG. 7B large segmented (for flexibility) electrodes E2, E3 are shown in the superior vena cava SVC near the atrium RA and in the right ventricle to serve as shocking electrodes to defibrillate a patient.
D. Various Alternative Embodiments FIG. 14 illustrates how the field can also be distorted by dielectric material DM
placed on a side of the electrodes E1, E2 opposite the septal wall S. The dielectric material DM result in a distortion of the electrical field biasing the left field lines LFL
toward the septal wall S and the free wall FW. Of course, this configuration will work even better with a reference electrode which will enhance the benefit.
While positioning of the electrodes El, Ea within the volume of the right ventricle RV is effective in combination with a reference electrode RE (FIG.
The present invention can be practiced with currently commercially available electrode leads and can also be enhanced with novel leads. FIG. 1 illustrates the invention in practice with such commercially available lead. As is the conventional usage for referencing relative direction, the terms "left" and "right" are used herein with reference to the patient's perspective. The terms "upper" and "lower" and similar terms such as "up" or "down" are used with reference to the base B of the heart being high and the apex A of the heart H being a lower end.
In FIG. 1, a patient's heart H is schematically shown in cross-section. The heart H includes the upper chambers of the right atrium RA and left atrium LA. The lower chambers are the right ventricle RV and left ventricle LV. Of the various venous vessels opening into the right atrium RA, only the superior vena cava SVC is shown.
Also, of the various heart valves, only the mitral valve MV (separating the left atrium LA from the left ventricle LV) and the tricuspid valve TV (separating the right atrium RA from the right ventricle RV) are shown. The septum S separates the right and left ventricles RV, LV and the free wall FW of the left ventricle LV is separately labeled.
The surface of the heart wall tissue opposing the chambers is the endocardium and is labeled as EN. The exterior surface of the heart is the epicardium and is labeled EP.
Not shown are coronary vessels of the heart or the pericardium surrounding the heart H.
In FIG. 1, an electrode lead is shown having a lead body LB1 and exposed electrodes El and E2. The first electrode E1 is positioned near the distal tip of the lead body LB1. The second electrode E2 is positioned more proximally on the lead body LB 1. . At the distal end, an attachment mechanism AM (such as a passive fixation design with tines or an active fixation design with a metallic helix) is shown for securing the first electrode E1 to the musculature of the heart H. The spacing of electrodes El, E2 could be greater than that of convention pacing electrodes permitting positioning of the first electrode E1 at the apex of the right ventricle RV
and the second electrode E2 in the right ventricle RV near the tricuspid valve TV. However, conventional leads with convention spacing have been used with the first or distal electrode attached to the septum (e.g., by a helix attachment HA) as shown in FIG. 7A.
The lead body LB1 is flexible and includes a bio-compatible, electrically insulating coating surrounding first and second conductors C1, C2 separately connected to the first and second electrodes E1, E2. In the various Figures, the lead bodies are broken at a line at the SVC to reveal the internal conductors C1, C2 extending to an implantable pulse generator IPG. In fact, the conductors C1, C2 are contained within the material of the lead body LB1 along their length. The term "implantable pulse generator IPG" is intended to include pacemakers, implantable converter defibrillators (ICD) and cardia resynchronization therapies (CRT), all known in the art.
The proximal end of the lead body terminates at a pin connector (not shown) as is customary. The pin connector has exposed electrical contacts uniquely connected to each of the conductors C1, C2. The pin connector may be releasably connected to the pulse generator IPG with the exposed contacts making electrical connection with unique contacts of the circuitry of the pulse generator IPG.
It will be appreciated that the prior art contains numerous examples of cardiac leads for placement in a chamber of the heart where the leads have, as described above, two or more electrodes spaced along a length of the lead, attachment mechanisms such as passive or active fixation and conductors and connector pins as described.
The current invention is not limited to pacing leads only, but rather is equally deployable with prior art ICD leads where it is customary to contain at least two electrodes in the RV. Such leads are selected of biocompatible material and treated (such as sterilized) for chronic placement in the patient.
The implantable pulse generator IPG is a small metallic container sealed for implantation in the patient and protecting internal circuitry. Commonly, such pulse generators are placed subcutaneously (e.g., in a dissected space between the skin and muscle layers of the patient). For cardiac pacing, such pulse generators are positioned in the upper chest on either the left or right front side of the patient near a shoulder.
However, placement need not be so restricted and such pulse generators could be placed in any convenient location selected by the physician.
Pulse generators contain internal circuitry for creating electrical impulses which are applied to the electrodes after the lead is connected to the pulse generator. Also, such circuitry may include sensing and amplification circuitry so that electrodes El, E2 may be used as sensing electrodes to sense and have the IPG report on the patient's electrophysiology.
The lead may be introduced to the vasculature through a small incision and advanced through the vasculature and into the right atrium RA and right ventricle to the position shown in FIG. 1. Such advancement typically occurs in an electrophysiology lab where the advancement of the lead can be visualized through fluoroscopy.
The pulse generator contains a battery as a power supply. With subcutaneous placement, replacement of a battery is well-known procedure. However, improvements in battery designs have resulted in longer-lasting batteries with the benefit of reducing the frequency of battery replacement. Alternatively, such batteries may be rechargeable in situ as is known in the art.
The pulse generator circuitry controls the parameters of the signals coupled to the electrodes E1, Ea. These parameters can include pulse amplitude, timing, pulse duration by way of example. The internal circuitry further includes circuit logic permitting reprogramming of the pulse generator to permit a physician to alter pacing parameters to suit the need of a particular patient. Such programming can be affected by inputting programming instructions to the pulse generator via wireless transmission from an external programmer. Pulse generators commonly include an exposed contact on the exterior of the generator housing. Such pulse generators may also be partially covered with an insulator such as silicone with a window formed in the silicone to expose a portion of the metallic housing which functions as a return electrode in so-called unipolar pacing. In conventional bipolar pacing, the window is not necessary.
Most commonly, the electrode is connected by the circuitry of the housing to an electrical ground. It will be appreciated that pulse generators as thus described are well known in the art and form no part of this invention per se.
While an implantable pulse generator is described in a preferred embodiment, the pulse generator may be external and coupled to the electrodes by percutaneous leads or wireless transmission. For example, a control of an implanted electrode is known for phrenic nerve stimulation and is described more fully in a product brochure "ATROSTIM PHRENIC NERVE STIMULATOR", AtroTech Oy, P.O. Box 28, FIN-33721, Tampere, Finland (June 2004). The Atrostim device sends signals from an external controller to an implanted antenna.
External pacing devices are typically used for providing temporary pacing therapy. The current invention is also believed to have advantages for this application as critically-ill patients requiring emergency, temporary pacing may also suffer further from asynchronous cardiac contraction associated with conventional RV pacing.
If desired, an external unit can be used to test a patient's suitability for the treatment.
Patient's who benefit from the therapy can then receive an implantable pulse generator for longer-term use.
B. Right Ventricle Electrodes Creating Left Ventricle-Stimulating Electrical Field FIGS. 1 and 8 illustrate commercially available leads and the associated electrical fields with both electrodes residing within the right ventricle with the distal electrode secured to the apex of the right ventricle. In FIG. 8, only the ventricles RV, LV are shown for ease of illustration. Also, for ease of illustration, FIG. 8 shows only the electrodes El, E2 without showing the remainder of the lead body LB 1.
While conventional bipolar leads are acceptable for use with the present invention, a wider spacing between electrodes E1, E2 can increase the field but can sacrifice some sensing capability. This trade-off can be mitigated by use of a three-electrode lead in the right ventricle RV. Such a lead would have a tip electrode and two ring electrodes, one located near the tip in the RV apex and one in the high part of the atrium, near the tricuspid valve. The sensing is performed between the tip and closer electrode. This will provide good so-called "near field" sensing and avoid so-called "far field" sensing of the atrium or skeletal muscles activity. The pacing could be between the ring electrodes to the return electrode located distally to the heart (as will be described). One could also combined the tip and nearest ring as one electrode to the return electrode and the other ring electrode to the return electrode at the opposite polarity.
The pulse generator IPG generates a first and a second pulsed waveform Wl, W2 applied, respectively, to the first and second electrodes E1, E2. FIG. 18 shows such waveforms Wi, W2. By way of example, and not intended to be limiting, the pulse duration PD is between about 0.1 to 2.0 milliseconds, the amplitude A may be 0.1 Volts to 10 or 20 Volts and the time delay TD between pulses is a targeting heart rate (e.g., 50 to 200 beats per minutes).
In FIG. 18, the pulses are shown as square waveforms but, in practice, can be any geometry. The first electrode El has positive charged pulses only. The second electrode E2 has negative charged pulses timed to coincide with the positive charged pulses of the positive electrode E1. While direct current (DC) pulses are preferred, the electrodes El, E2 could be energized with alternating current pulses with the signals to the electrodes El, E2 out of phase such that the positive pulses on the first electrode El coincide with negative pulses on the second electrode E2 and negative pulses on the first electrode El coincide with positive pulses on the second electrode E2.
With the electrodes El, EZ charged with opposite pulses, it is Applicants' current understanding that an electrical field is created between the electrodes E1, E2 with a field axis FA (FIG. 8) extending in a line between the electrodes EI, E2. In the absence of distorting influences (such as external magnetic fields, external electrodes or non-homogonous conductivity due to variances in conductivity of blood, tissue bone, etc.), the field is symmetrical about the field axis FA and is represented by field lines illustrated in the drawings as left field lines LFL to the left of the axis FA
(with left being from the patient's perspective) and right field lines RFL. The field lines represent the intensity of the electrical field. The intensity diminishes rapidly as a function of the distance from the field axis FA.
In the embodiment of FIG. 1, in order for the fields generated by the electrodes EI, E2 to have a significant influence on both the septal walls and the free wall FW of the left ventricle LV, a voltage potential across the electrodes must be substantially high. However, such high voltages are not practical in a pacing electrode and are more normally associated with defibrillating treatments. Also, such voltages would cause an extremely significant drain on a battery requiring impractical frequency of battery replacement.
C. Improving Field Influence on Left Ventricle FIG. 9 illustrates benefits associated with movement of the electrodes El, E2 from the interior of the right ventricle RV (FIGS. 1 and 8) to direct placement of the electrodes E1, E2 on the septal wall S. Such movement shifts the field lines toward both the septal wall S and the free wall FW of the left ventricle LV. However, it is believed that even with such improvement, voltages required for effective stimulation of the septal wall and the free wall of the left ventricle would be impractically high.
The present invention utilizes a reference electrode RE in combination with the electrodes E1, E2 in the right ventricle to result in effective pacing of the left ventricle LV. Although the physics and physiology of the mechanism of action are not fully understood, it is presently believed that the reference electrode RE distorts the electromagnetic field otherwise created between the right ventricle electrodes E1, Ez to urge an intensity of the electromagnetic field deeper into the septal wall S
of the left ventricle LV. It is believed this occurs by creating a third high current density spot (or spots) away from the two electrodes in the wall and towards the reference electrode at the point where the current flows between the electrode El and the reference electrode RE and between the electrode E2 and the reference electrode RE coincide in space and time. This is illustrated in FIG. 10. Such a phenomenon is believed to facilitate the activation of the surviving conduction fibers in the Left Bundle Branch Block (LBBB) patients and Purkinje fibers and create a more rapid and uniform activation of the left ventricle LV that follows a similar pattern to the normal activation present in patients without LBBB.
The reference electrode may be physically attached to the housing of the implantable pulse generator IPG (and thereby having a neutral charge). Such an electrode RE is shown in FIGS. 1 - 7B. It will be appreciated that the reference electrode RE can be connected to the implantable pulse generator IPG by a conductor.
The reference electrode could be another common electrode that exists in the conventional pacing or ICD system, such as an electrode in the atrium or a defibrillation coil electrode situated in the SVC, RA or RV.
As shown in FIG. 10, the consequence of the reference electrode RE is presently believed to have a deforming effect on the electromagnetic field generated between the first and second electrodes El, E2. This is illustrated in FIG. 10 by distorting the left field lines LFL toward the septal wall S and free wall FW of the left ventricle LV.
Also, the right field lined RFL are compressed toward the axis FA to alter the field from the symmetric presentation of FIGS. 8 and 9 to the asymmetric presentation of FIG. 10 with the field biased toward the septal wall S and the free wall FW of the left ventricle LV.
It has been found that within energy levels associated with available implantable pulse generators (up to 10 or 20 volts) effective activation of the left ventricle LV can be achieved with the pacing arrangement of FIG 7A, where the first electrode El is attached to the mid- or upper-septum. In such arrangement, the reference electrode RE
is on the housing of the generator IPG and positioned subcutaneously near the right or left shoulder. The re-direction of the field as described, the inventors believe, may also be useful in decreasing defibrillation thresholds if arrangement similar to FIG. 7B is used. In FIG. 7B large segmented (for flexibility) electrodes E2, E3 are shown in the superior vena cava SVC near the atrium RA and in the right ventricle to serve as shocking electrodes to defibrillate a patient.
D. Various Alternative Embodiments FIG. 14 illustrates how the field can also be distorted by dielectric material DM
placed on a side of the electrodes E1, E2 opposite the septal wall S. The dielectric material DM result in a distortion of the electrical field biasing the left field lines LFL
toward the septal wall S and the free wall FW. Of course, this configuration will work even better with a reference electrode which will enhance the benefit.
While positioning of the electrodes El, Ea within the volume of the right ventricle RV is effective in combination with a reference electrode RE (FIG.
10), movement of the electrodes El, E2 directly against the septal wall S may further enhance the therapeutic benefit of the present invention for reasons described above.
Various techniques for movement of the electrodes El, E2 against the septal wall S are disclosed.
FIG. 2 illustrates a lead body LB2 in the right ventricle RV with the electrodes El, E2 directly placed on the septal wall S and held in place against the septal wall through any suitable means. For example, FIG. 2A illustrates one embodiment for attachment of an electrode against the septal wall. The lead body LB2 is shown has having an internal lumen LU with a port PO near an electrode (e.g., electrode E2). Any suitable attachment mechanism (such as a pigtail guidewire or an injected bio-adhesive) can be passed through the lumen LU and port PO to fix the electrode E2 in abutment against the septal wall S. Further, a guide catheter could also be used in moving the implantable lead to assist in the mapping of the optimal location of the septum. The optimal lead location can be determined with the assistance of the surface ECG
parameters (e.g. QRS width and/or activation vectors).
FIG. 3 illustrates the electrodes El, E2 against the septal wall S but without requiring an attachment mechanism. Instead, an intermediate region IR of the lead body LB3 is formed of shaped memory material (such as nitinol) to assume an S-shaped configuration and urge the electrodes E1, Ez against the septal wall S.
In FIG. 4, the lead body LB4 has two components LBa, LBb joined by an intermediate section IS which may be formed of any elastomeric material (such as a shaped memory material). The intermediate section IS is biased to urge the two components LBa, LBb into collinear alignment. With the intermediate section IS
placed against the apex of the right ventricle RV, the bias of the intermediate section IS urges the electrodes E1, E2 against the septal wall S.
FIG. 5 illustrates the electrodes E1, E2 individually placed on the septal wall S
and not retained on a lead body. In such an embodiment, the electrodes El, Ea may be energized in a pacing waveform by wireless transmission signals Tl, T2 from the implantable pulse generator IPG. Wireless transmission from a controller to an electrode is shown in U.S. Patent No. 6,907,285 to Denker, et al., dated June 14, 2004.
Alternatively, the electrodes E1, E2 may be directly imbedded as microstimulators into the tissue of the septal wall S as illustrated in FIG. 6. Microstimulators for implantation into human tissue are shown in U.S. patent application Publ. No. 2004/0153127 published August 5, 2004.
The positioning of the reference electrode RE may be directly on the housing of the implantable pulse generator IPG or may be separate from the internal pulse generator as previously mentioned. While not preferred, the reference electrode RE can be placed in the left ventricle (FIG. 11) (or in the tissue of the free wall FW as shown in phantom lines in FIG. 11), on the epicardial surface (FIG. 12) or in the coronary sinus CS (FIG. 13).
Positioning the reference electrode RE relative to the heart can affect the distortion of the field in the area of the left ventricle free wall FW subject to pacing.
Particularly for a subcutaneously placed reference electrode (which is preferred to minimize the invasive nature of the procedure), the electrical conduction path from the right ventricle RV to the reference electrode will vary considerably between patients.
Also, the direction of field distortion may alter the region of the left ventricle LV subject to pacing. For example, FIG. 15 illustrates the reference electrode REl placed high relative to the heart resulting in a distortion of the field toward the upper end of the left ventricle septum and free wall FW. FIG. 16 illustrates placement of a reference electrode RE2 lower relative to the heart and to deflect the intensity of the field toward the lower end of the left ventricle septum and free wall FW.
While the reference electrode could be a single electrode, multiple electrodes could be provided for subcutaneous placement and each connected by a switch circuitry SW of the implantable pulse generator as illustrated in FIGS. 15 and 16. The patient's response can be noted with each of the several reference electrodes RE1, RE2 separately connected to the ground or housing of the implantable pulse generator. The patient can then be treated with the electrode showing the most effectiveness for the particular patient. Further, over time, a patient's response may change and the implantable pulse generator can be reprogrammed to select any one of the other reference electrodes as the switched electrode.
In addition, the catheter LB5 within the right ventricle can have multiple electrodes along its length (as shown in FIG.7). Individual pairs of these electrodes Et - E4 can be switched on or off over time so that the appropriate pair of electrodes within the right ventricle is selected for optimized left ventricular pacing.
FIG. 19 illustrates a representative circuit in schematic format for a portion of a cardiac stimulation pulse generator that is capable of providing pacing output for either the conventional design or the present invention. The circuit of FIG. 19 could be for an implantable pacemaker or any external stimulation system for diagnostic or therapeutic use.
The stimulation device has three output terminals that are connected to three electrodes El, E2, RE in the body. Electrodes E1, EZ are positioned in the right ventricle RV with it being preferred that at least one of these electrodes be in direct contact with the septum S.
The reference electrode RE is an indifferent electrode which can be connected electronically to the housing of the implantable pulse generator IPG. The reference electrode RE may be an electrode directly on the implantable pulse generator or any other electrode for placement inside or outside of the heart as described above.
In the preferred embodiment, the reference electrode is grounded to the housing of the implantable pulse generator. FIG. 17 illustrates an alternative embodiment where the reference electrode includes two active electrodes AE1, AE2 external to the heart.
The active electrodes AEI, AE2 are paced with pulsed waveforms which are polar opposites of the waveforms on electrodes E1, E2. This creates dual uni-polar field Fl, F2 in addition to the left field lines LFL previously described.
In the Figure, the amplitude of the waveforms from FIG. 18 (or other waveform as described) is shown in phantom lines as the battery voltage applied to the four poles on the left of FIG. 19 to charge the two pacing capacitor C1 and C2. Details of the charging circuitry as well as other controlling circuitry for pacing and sensing are omitted for ease of illustration, but should be customary to those skilled in the art. Only capacitor Cl needs to be charged for the conventional pacing output, whereas both Cl and C2 need to be charged for the present invention. Capacitor C3 and C4 are for the pacing output coupling to the patient. For ease of illustration and explanation, the output waveform from FIG. 18 with the same amplitude and simultaneous timing is assumed for the design schematic in FIG. 19. A switch S1 permits selection between unipolar conventional pacing and pacing according to the present invention (by contact with switch pole Al) or bi-polar conventional pacing (by contact with switch pole A2).
Selection between conventional pacing or the present invention is made by applying a digital signal with the timing information as shown in FIG. 18 to either T1 or T1 and T2, namely to either toggle the switch S5 or S2 and S5 simultaneously). An AND
gate is used to allow the close of the switch S2 only for pacing according to the present invention. Switches S3 and S4 permit re-neutralizing the pacing charges at the patient-electrode interface.
As is customary with implantable pulse generators, the device may be programmable to achieve either conventional bipolar or unipolar stimulation or to achieve the stimulation of the present invention through an external programmer or controlled automatically by the device. The selection can be based on user preference or be driven by physiological factors such as widths of the patient's QRS
complex or the conduction interval between the stimulus to a far away region in the heart. In addition switching between the pacing of the present invention and conventional pacing can also be determined by the percentage of pacing with a preference for a higher percentage with the pacing of the present invention. Further, the switching from the conventional pacing to the present invention pacing can be used when there exists an exit block or the pacing electrode is located in infracted myocardium when conventional pacing can not effect the depolarization of the myocardium at the high output level. The automatic determination can be effected through the deployment of any automatic capture detection technology that exists in the prior art. Additionally, wireless network enabled switching function for therapy optimization can also be implemented with the present invention. In such case, certain patient physiologic data are gathered by the implantable device and sent to a remote server/monitor through a wireless communication network.
FIG. 18 illustrates a preferred waveform with electrodes E1, E2 being simultaneously pulsed with opposite polarity. FIG. 18A illustrates waveforms Wl', W2' of similar structure to the waveforms of FIG. 18 but slightly out of phase to present a partial overlap duration DO. With FIGS. 18A at least a portion of time includes a monopolar pacing from individual ones of the electrodes EI, EZ to the reference electrode RE. This pacing creates out of phase monopolar fields Fl, F2 as illustrated in FIG. 18B. While the amplitudes of the two waveforms are shown equal, they need not be equal in practice.
The present invention can also be extended to the defibrillation therapy where high-energy pulses with various waveforms are delivered through electrode systems to treat tachycardia and fibrillation (both atrium and ventricle). The present invention is believed to be able to achieve lower defibrillation threshold due to better distribution of the electrical field, causing higher voltage gradient at least in certain parts of the heart compared to that by the conventional defibrillation configuration as seen in FIG. 7B.
Additionally, the present invention can be used to perform anti-tachy pacing where faster than conventional pacing pulse sequences are used to stop certain tachyarrhythmia. The present invention is believed to be advantageous due to the wider coverage of the electrical field and the capability of capturing special conductions system in the heart (both atrium and ventricle).
While cardiac applications are a most preferred einbodiment, the present application is applicable to other therapies where high current density spot(s) away from the electrodes are beneficial for stimulating the target, including but not limited to nerves, muscle, gastric and intestine system, and cortex). For example, U.S.
Pat. No.
5,299,569 to Wernicke et al. issued April 5, 1994 (and incorporated herein by reference is one of a number of patents assigned to Cyberonics, Inc. describes pacing the vagus nerve to treat a wide variety of disorders. Pacing electrodes are applied directly to the vagus nerve in, for example, the neck. Application of an electrode directly to the vagus nerve creates risk of mechanical injury (e.g., pressure necrosis) to the nerve. FIG. 20 illustrates use of the present invention in such application. Electrodes E1, E2 are placed subcutaneously near (trancutarieously or transvenously coupled) but not on the vagus nerve VN in the neck. A reference electrode RE is placed subcutaneously (trancutaneously or transvenously coupled) on an opposite side of the nerve VN. The electrodes E1, E2 and RE are connected to a pulse generator IPG. With signals as described above, the resulting field F captures the vagus nerve. The signals may be selected to have amplitude, frequency and other parameters as more fully described in the '569 patent. It will be appreciated that other alternative examples of using the present invention to pace an organ or the nerve will occur to one of ordinary skill in the art with the benefit of the teachings of the present invention.
It has been shown how the objects of the invention have been achieved in a preferred embodiment. Modifications and equivalents of the disclosed concepts are intended to be included within the scope of the claims appended hereto.
Various techniques for movement of the electrodes El, E2 against the septal wall S are disclosed.
FIG. 2 illustrates a lead body LB2 in the right ventricle RV with the electrodes El, E2 directly placed on the septal wall S and held in place against the septal wall through any suitable means. For example, FIG. 2A illustrates one embodiment for attachment of an electrode against the septal wall. The lead body LB2 is shown has having an internal lumen LU with a port PO near an electrode (e.g., electrode E2). Any suitable attachment mechanism (such as a pigtail guidewire or an injected bio-adhesive) can be passed through the lumen LU and port PO to fix the electrode E2 in abutment against the septal wall S. Further, a guide catheter could also be used in moving the implantable lead to assist in the mapping of the optimal location of the septum. The optimal lead location can be determined with the assistance of the surface ECG
parameters (e.g. QRS width and/or activation vectors).
FIG. 3 illustrates the electrodes El, E2 against the septal wall S but without requiring an attachment mechanism. Instead, an intermediate region IR of the lead body LB3 is formed of shaped memory material (such as nitinol) to assume an S-shaped configuration and urge the electrodes E1, Ez against the septal wall S.
In FIG. 4, the lead body LB4 has two components LBa, LBb joined by an intermediate section IS which may be formed of any elastomeric material (such as a shaped memory material). The intermediate section IS is biased to urge the two components LBa, LBb into collinear alignment. With the intermediate section IS
placed against the apex of the right ventricle RV, the bias of the intermediate section IS urges the electrodes E1, E2 against the septal wall S.
FIG. 5 illustrates the electrodes E1, E2 individually placed on the septal wall S
and not retained on a lead body. In such an embodiment, the electrodes El, Ea may be energized in a pacing waveform by wireless transmission signals Tl, T2 from the implantable pulse generator IPG. Wireless transmission from a controller to an electrode is shown in U.S. Patent No. 6,907,285 to Denker, et al., dated June 14, 2004.
Alternatively, the electrodes E1, E2 may be directly imbedded as microstimulators into the tissue of the septal wall S as illustrated in FIG. 6. Microstimulators for implantation into human tissue are shown in U.S. patent application Publ. No. 2004/0153127 published August 5, 2004.
The positioning of the reference electrode RE may be directly on the housing of the implantable pulse generator IPG or may be separate from the internal pulse generator as previously mentioned. While not preferred, the reference electrode RE can be placed in the left ventricle (FIG. 11) (or in the tissue of the free wall FW as shown in phantom lines in FIG. 11), on the epicardial surface (FIG. 12) or in the coronary sinus CS (FIG. 13).
Positioning the reference electrode RE relative to the heart can affect the distortion of the field in the area of the left ventricle free wall FW subject to pacing.
Particularly for a subcutaneously placed reference electrode (which is preferred to minimize the invasive nature of the procedure), the electrical conduction path from the right ventricle RV to the reference electrode will vary considerably between patients.
Also, the direction of field distortion may alter the region of the left ventricle LV subject to pacing. For example, FIG. 15 illustrates the reference electrode REl placed high relative to the heart resulting in a distortion of the field toward the upper end of the left ventricle septum and free wall FW. FIG. 16 illustrates placement of a reference electrode RE2 lower relative to the heart and to deflect the intensity of the field toward the lower end of the left ventricle septum and free wall FW.
While the reference electrode could be a single electrode, multiple electrodes could be provided for subcutaneous placement and each connected by a switch circuitry SW of the implantable pulse generator as illustrated in FIGS. 15 and 16. The patient's response can be noted with each of the several reference electrodes RE1, RE2 separately connected to the ground or housing of the implantable pulse generator. The patient can then be treated with the electrode showing the most effectiveness for the particular patient. Further, over time, a patient's response may change and the implantable pulse generator can be reprogrammed to select any one of the other reference electrodes as the switched electrode.
In addition, the catheter LB5 within the right ventricle can have multiple electrodes along its length (as shown in FIG.7). Individual pairs of these electrodes Et - E4 can be switched on or off over time so that the appropriate pair of electrodes within the right ventricle is selected for optimized left ventricular pacing.
FIG. 19 illustrates a representative circuit in schematic format for a portion of a cardiac stimulation pulse generator that is capable of providing pacing output for either the conventional design or the present invention. The circuit of FIG. 19 could be for an implantable pacemaker or any external stimulation system for diagnostic or therapeutic use.
The stimulation device has three output terminals that are connected to three electrodes El, E2, RE in the body. Electrodes E1, EZ are positioned in the right ventricle RV with it being preferred that at least one of these electrodes be in direct contact with the septum S.
The reference electrode RE is an indifferent electrode which can be connected electronically to the housing of the implantable pulse generator IPG. The reference electrode RE may be an electrode directly on the implantable pulse generator or any other electrode for placement inside or outside of the heart as described above.
In the preferred embodiment, the reference electrode is grounded to the housing of the implantable pulse generator. FIG. 17 illustrates an alternative embodiment where the reference electrode includes two active electrodes AE1, AE2 external to the heart.
The active electrodes AEI, AE2 are paced with pulsed waveforms which are polar opposites of the waveforms on electrodes E1, E2. This creates dual uni-polar field Fl, F2 in addition to the left field lines LFL previously described.
In the Figure, the amplitude of the waveforms from FIG. 18 (or other waveform as described) is shown in phantom lines as the battery voltage applied to the four poles on the left of FIG. 19 to charge the two pacing capacitor C1 and C2. Details of the charging circuitry as well as other controlling circuitry for pacing and sensing are omitted for ease of illustration, but should be customary to those skilled in the art. Only capacitor Cl needs to be charged for the conventional pacing output, whereas both Cl and C2 need to be charged for the present invention. Capacitor C3 and C4 are for the pacing output coupling to the patient. For ease of illustration and explanation, the output waveform from FIG. 18 with the same amplitude and simultaneous timing is assumed for the design schematic in FIG. 19. A switch S1 permits selection between unipolar conventional pacing and pacing according to the present invention (by contact with switch pole Al) or bi-polar conventional pacing (by contact with switch pole A2).
Selection between conventional pacing or the present invention is made by applying a digital signal with the timing information as shown in FIG. 18 to either T1 or T1 and T2, namely to either toggle the switch S5 or S2 and S5 simultaneously). An AND
gate is used to allow the close of the switch S2 only for pacing according to the present invention. Switches S3 and S4 permit re-neutralizing the pacing charges at the patient-electrode interface.
As is customary with implantable pulse generators, the device may be programmable to achieve either conventional bipolar or unipolar stimulation or to achieve the stimulation of the present invention through an external programmer or controlled automatically by the device. The selection can be based on user preference or be driven by physiological factors such as widths of the patient's QRS
complex or the conduction interval between the stimulus to a far away region in the heart. In addition switching between the pacing of the present invention and conventional pacing can also be determined by the percentage of pacing with a preference for a higher percentage with the pacing of the present invention. Further, the switching from the conventional pacing to the present invention pacing can be used when there exists an exit block or the pacing electrode is located in infracted myocardium when conventional pacing can not effect the depolarization of the myocardium at the high output level. The automatic determination can be effected through the deployment of any automatic capture detection technology that exists in the prior art. Additionally, wireless network enabled switching function for therapy optimization can also be implemented with the present invention. In such case, certain patient physiologic data are gathered by the implantable device and sent to a remote server/monitor through a wireless communication network.
FIG. 18 illustrates a preferred waveform with electrodes E1, E2 being simultaneously pulsed with opposite polarity. FIG. 18A illustrates waveforms Wl', W2' of similar structure to the waveforms of FIG. 18 but slightly out of phase to present a partial overlap duration DO. With FIGS. 18A at least a portion of time includes a monopolar pacing from individual ones of the electrodes EI, EZ to the reference electrode RE. This pacing creates out of phase monopolar fields Fl, F2 as illustrated in FIG. 18B. While the amplitudes of the two waveforms are shown equal, they need not be equal in practice.
The present invention can also be extended to the defibrillation therapy where high-energy pulses with various waveforms are delivered through electrode systems to treat tachycardia and fibrillation (both atrium and ventricle). The present invention is believed to be able to achieve lower defibrillation threshold due to better distribution of the electrical field, causing higher voltage gradient at least in certain parts of the heart compared to that by the conventional defibrillation configuration as seen in FIG. 7B.
Additionally, the present invention can be used to perform anti-tachy pacing where faster than conventional pacing pulse sequences are used to stop certain tachyarrhythmia. The present invention is believed to be advantageous due to the wider coverage of the electrical field and the capability of capturing special conductions system in the heart (both atrium and ventricle).
While cardiac applications are a most preferred einbodiment, the present application is applicable to other therapies where high current density spot(s) away from the electrodes are beneficial for stimulating the target, including but not limited to nerves, muscle, gastric and intestine system, and cortex). For example, U.S.
Pat. No.
5,299,569 to Wernicke et al. issued April 5, 1994 (and incorporated herein by reference is one of a number of patents assigned to Cyberonics, Inc. describes pacing the vagus nerve to treat a wide variety of disorders. Pacing electrodes are applied directly to the vagus nerve in, for example, the neck. Application of an electrode directly to the vagus nerve creates risk of mechanical injury (e.g., pressure necrosis) to the nerve. FIG. 20 illustrates use of the present invention in such application. Electrodes E1, E2 are placed subcutaneously near (trancutarieously or transvenously coupled) but not on the vagus nerve VN in the neck. A reference electrode RE is placed subcutaneously (trancutaneously or transvenously coupled) on an opposite side of the nerve VN. The electrodes E1, E2 and RE are connected to a pulse generator IPG. With signals as described above, the resulting field F captures the vagus nerve. The signals may be selected to have amplitude, frequency and other parameters as more fully described in the '569 patent. It will be appreciated that other alternative examples of using the present invention to pace an organ or the nerve will occur to one of ordinary skill in the art with the benefit of the teachings of the present invention.
It has been shown how the objects of the invention have been achieved in a preferred embodiment. Modifications and equivalents of the disclosed concepts are intended to be included within the scope of the claims appended hereto.
Claims (14)
1. ~A method for treating a condition of a heart of a patient, said method comprising:
placing a first electrode and a second electrode in a right ventricle of said heart;
placing a reference electrode within said patient and internal or external to said heart;
generating a pacing signal including a first signal component, a second signal component and a reference component with said first and second signal components having opposite polarity and with both of said first and second components having a potential relative to said reference component;
transmitting said first component to said first electrode, said second component to said second electrode and said reference component to said reference electrode;
said pacing signal and said placement of said electrodes selected to alter a contraction of a left ventricle of said heart.
placing a first electrode and a second electrode in a right ventricle of said heart;
placing a reference electrode within said patient and internal or external to said heart;
generating a pacing signal including a first signal component, a second signal component and a reference component with said first and second signal components having opposite polarity and with both of said first and second components having a potential relative to said reference component;
transmitting said first component to said first electrode, said second component to said second electrode and said reference component to said reference electrode;
said pacing signal and said placement of said electrodes selected to alter a contraction of a left ventricle of said heart.
2. ~A method according to claim 1 wherein at least one of said first and second electrodes is secured to a septum of said heart.
3. ~A method according to claim 1 wherein said reference electrode is positioned to bias a field between said first and second electrodes toward a region that allows more synchronous contraction of the left ventricle.
4. ~A method according to claim 1 wherein said reference electrode is one of a plurality of reference electrodes connected by a switch to said reference component.
5. A method according to claim 1 wherein said reference electrode is positioned within said patient body to distort a field from said first and second electrodes to said left ventricle.
6. An apparatus for treating a condition of a heart of a patient, said apparatus comprising:
a first electrode and a second electrode each adapted for placement in a right ventricle of said heart;
a reference electrode adapted for placement within said patient and internal or external to said heart;
a signal generator for generating a pacing signal including a first signal component, a second signal component and a reference component with said first and second signal components having opposite polarity and with both of said first and second components having a potential relative to said reference component;
said signal generator coupled to said electrodes for transmitting said first component to said first electrode, said second component to said second electrode and said reference component to said reference electrode;
said pacing signal and said placement of said electrodes selected to alter a contraction of a left ventricle of said heart.
a first electrode and a second electrode each adapted for placement in a right ventricle of said heart;
a reference electrode adapted for placement within said patient and internal or external to said heart;
a signal generator for generating a pacing signal including a first signal component, a second signal component and a reference component with said first and second signal components having opposite polarity and with both of said first and second components having a potential relative to said reference component;
said signal generator coupled to said electrodes for transmitting said first component to said first electrode, said second component to said second electrode and said reference component to said reference electrode;
said pacing signal and said placement of said electrodes selected to alter a contraction of a left ventricle of said heart.
7. An apparatus according to claim 6 wherein said transmitting is by wireless transmission.
8. An apparatus according to claim 6 wherein said signal generator further includes circuitry for switching from said pacing to a second pacing mode.
9. An apparatus according to claim 6 further comprising multiple reference electrodes with a switch for selecting a particular one of said multiple reference electrodes to be connected to said reference component.
10. An apparatus according to claim 6 further comprising a lead with at least one electrode adapted to be placed in said atrium and energized: with a pacing/sensing circuitry to facilitate atrial-ventricular sequential pacing.
11. An apparatus according to claim 6 further comprising a lead with and electrode adapted to be placed on said left ventricle and energized with a pacing/sensing circuitry.
12. An apparatus according to claim 6 further comprising a defibrillation lead system with at least one large shocking electrode and circuitry for energize the said defibrillation electrode system (including, but not limited to the shocking electrode and the IPG housing) for defibrillation therapy.
13. An apparatus according to claim 6 wherein said first and second electrodes are of a plurality of electrodes adapted for placement in said right ventricle, said signal generator including circuitry for selectively connecting one of said plurality to said first component and a second of said plurality to said second component.
14. An apparatus according to claim 6 including at least two reference electrodes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP040104782 | 2004-12-20 | ||
ARP040104782A AR047851A1 (en) | 2004-12-20 | 2004-12-20 | A NEW MARCAPASOS THAT RESTORES OR PRESERVES THE PHYSIOLOGICAL ELECTRIC DRIVING OF THE HEART AND A METHOD OF APPLICATION |
PCT/US2005/045044 WO2006068880A1 (en) | 2004-12-20 | 2005-12-13 | Ventricular pacing |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2591121A1 true CA2591121A1 (en) | 2006-06-29 |
Family
ID=36597106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002591121A Abandoned CA2591121A1 (en) | 2004-12-20 | 2005-12-13 | Ventricular pacing |
Country Status (7)
Country | Link |
---|---|
US (7) | US7512440B2 (en) |
EP (1) | EP1830920B1 (en) |
JP (2) | JP5307401B2 (en) |
AR (1) | AR047851A1 (en) |
AU (1) | AU2005319498B2 (en) |
CA (1) | CA2591121A1 (en) |
WO (1) | WO2006068880A1 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1571694A4 (en) * | 2002-12-10 | 2008-10-15 | Nikon Corp | Exposure apparatus and method for manufacturing device |
US7392094B2 (en) | 2002-12-19 | 2008-06-24 | Cardiac Pacemakers, Inc. | Implantable lead for septal placement of pacing electrodes |
US20050149860A1 (en) * | 2002-12-27 | 2005-07-07 | Casio Computer Co., Ltd. | Electronic device manufacture support apparatus, manufacture client terminal device, and recording medium |
US20040147994A1 (en) * | 2003-01-28 | 2004-07-29 | Cardiac Pacemakers, Inc. | Tachy lead system optimized for septal placement |
US7532933B2 (en) | 2004-10-20 | 2009-05-12 | Boston Scientific Scimed, Inc. | Leadless cardiac stimulation systems |
US7647109B2 (en) * | 2004-10-20 | 2010-01-12 | Boston Scientific Scimed, Inc. | Leadless cardiac stimulation systems |
WO2006045075A1 (en) | 2004-10-20 | 2006-04-27 | Boston Scientific Limited | Leadless cardiac stimulation systems |
WO2006054057A2 (en) * | 2004-11-16 | 2006-05-26 | Gw Pharma Limited | New use for cannabinoid |
US8014861B2 (en) * | 2004-12-20 | 2011-09-06 | Cardiac Pacemakers, Inc. | Systems, devices and methods relating to endocardial pacing for resynchronization |
US8050756B2 (en) | 2004-12-20 | 2011-11-01 | Cardiac Pacemakers, Inc. | Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management |
US8326423B2 (en) | 2004-12-20 | 2012-12-04 | Cardiac Pacemakers, Inc. | Devices and methods for steering electrical stimulation in cardiac rhythm management |
US8005544B2 (en) | 2004-12-20 | 2011-08-23 | Cardiac Pacemakers, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
US8423139B2 (en) | 2004-12-20 | 2013-04-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for cardiac rhythm management using an electrode arrangement |
US8010192B2 (en) * | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Endocardial pacing relating to conduction abnormalities |
AR047851A1 (en) | 2004-12-20 | 2006-03-01 | Giniger Alberto German | A NEW MARCAPASOS THAT RESTORES OR PRESERVES THE PHYSIOLOGICAL ELECTRIC DRIVING OF THE HEART AND A METHOD OF APPLICATION |
US8010191B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Systems, devices and methods for monitoring efficiency of pacing |
US8290586B2 (en) * | 2004-12-20 | 2012-10-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device |
US7962208B2 (en) | 2005-04-25 | 2011-06-14 | Cardiac Pacemakers, Inc. | Method and apparatus for pacing during revascularization |
EP1957147B1 (en) | 2005-12-09 | 2010-12-29 | Boston Scientific Scimed, Inc. | Cardiac stimulation system |
US8050774B2 (en) | 2005-12-22 | 2011-11-01 | Boston Scientific Scimed, Inc. | Electrode apparatus, systems and methods |
US7885710B2 (en) | 2005-12-23 | 2011-02-08 | Cardiac Pacemakers, Inc. | Method and apparatus for tissue protection against ischemia using remote conditioning |
US7937161B2 (en) * | 2006-03-31 | 2011-05-03 | Boston Scientific Scimed, Inc. | Cardiac stimulation electrodes, delivery devices, and implantation configurations |
US8255049B2 (en) | 2006-05-08 | 2012-08-28 | Cardiac Pacemakers, Inc. | Method and device for providing anti-tachyarrhythmia therapy |
US20070282376A1 (en) | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for neural stimulation via the lymphatic system |
US8290600B2 (en) * | 2006-07-21 | 2012-10-16 | Boston Scientific Scimed, Inc. | Electrical stimulation of body tissue using interconnected electrode assemblies |
US7840281B2 (en) | 2006-07-21 | 2010-11-23 | Boston Scientific Scimed, Inc. | Delivery of cardiac stimulation devices |
WO2008034005A2 (en) * | 2006-09-13 | 2008-03-20 | Boston Scientific Scimed, Inc. | Cardiac stimulation using leadless electrode assemblies |
US8068920B2 (en) | 2006-10-03 | 2011-11-29 | Vincent A Gaudiani | Transcoronary sinus pacing system, LV summit pacing, early mitral closure pacing, and methods therefor |
US8983598B2 (en) * | 2006-10-04 | 2015-03-17 | Cardiac Pacemakers, Inc. | System for neurally-mediated anti-arrhythmic therapy |
US8214007B2 (en) * | 2006-11-01 | 2012-07-03 | Welch Allyn, Inc. | Body worn physiological sensor device having a disposable electrode module |
US7787950B1 (en) * | 2006-11-03 | 2010-08-31 | Pacesetter, Inc. | Techniques for delivery of stem cell and related therapies to treat cardiac conditions |
US20080154328A1 (en) * | 2006-12-15 | 2008-06-26 | Proteus Biomedical, Inc. | Universal connector for implantable medical device |
JP5588340B2 (en) * | 2007-06-29 | 2014-09-10 | カーディアック ペースメイカーズ, インコーポレイテッド | Method, apparatus and system for management of cardiac rhythm using electrode configuration |
WO2009006331A1 (en) * | 2007-06-29 | 2009-01-08 | Action Medical, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
JP2010532231A (en) * | 2007-06-29 | 2010-10-07 | アクション メディカル インコーポレイテッド | Cardiac rhythm management method, management apparatus, and management system using electrode configuration |
US8738147B2 (en) | 2008-02-07 | 2014-05-27 | Cardiac Pacemakers, Inc. | Wireless tissue electrostimulation |
US8849395B2 (en) * | 2008-05-30 | 2014-09-30 | Boston Scientific Scimed, Inc. | Guide catheter having vasomodulating electrodes |
US9037235B2 (en) | 2008-06-19 | 2015-05-19 | Cardiac Pacemakers, Inc. | Pacing catheter with expandable distal end |
US8244352B2 (en) | 2008-06-19 | 2012-08-14 | Cardiac Pacemakers, Inc. | Pacing catheter releasing conductive liquid |
US9409012B2 (en) | 2008-06-19 | 2016-08-09 | Cardiac Pacemakers, Inc. | Pacemaker integrated with vascular intervention catheter |
US8639357B2 (en) | 2008-06-19 | 2014-01-28 | Cardiac Pacemakers, Inc. | Pacing catheter with stent electrode |
US8457738B2 (en) | 2008-06-19 | 2013-06-04 | Cardiac Pacemakers, Inc. | Pacing catheter for access to multiple vessels |
WO2010002456A1 (en) * | 2008-07-01 | 2010-01-07 | Cardiac Pacemakers, Inc. | Pacing system controller integrated into indeflator |
EP2309918B1 (en) * | 2008-07-29 | 2021-03-17 | Koninklijke Philips N.V. | System for communicating information between implantable devices |
JP4545210B2 (en) * | 2008-09-11 | 2010-09-15 | 日本ライフライン株式会社 | Defibrillation catheter |
JP5319776B2 (en) * | 2008-10-10 | 2013-10-16 | カーディアック ペースメイカーズ, インコーポレイテッド | Single-chamber pacing using a dual-chamber pacing device |
WO2010071849A2 (en) * | 2008-12-19 | 2010-06-24 | Action Medical, Inc. | Devices, methods, and systems including cardiac pacing |
JP4545216B1 (en) | 2009-03-23 | 2010-09-15 | 日本ライフライン株式会社 | Intracardiac defibrillation catheter system |
EP2421605B1 (en) | 2009-04-23 | 2017-07-12 | Impulse Dynamics NV | Implantable lead connector |
US9072890B2 (en) | 2009-09-03 | 2015-07-07 | Mayo Foundation For Medical Education And Research | Pacing, sensing or defibrillator leads for implantation into the myocardium |
US20110224606A1 (en) * | 2010-03-10 | 2011-09-15 | Shibaji Shome | Method and apparatus for remote ischemic conditioning during revascularization |
US8565880B2 (en) | 2010-04-27 | 2013-10-22 | Cardiac Pacemakers, Inc. | His-bundle capture verification and monitoring |
US8954147B2 (en) | 2010-10-22 | 2015-02-10 | Cardiac Pacemakers, Inc. | Timing for His-bundle pacing |
WO2012125273A2 (en) | 2011-03-14 | 2012-09-20 | Cardiac Pacemakers, Inc. | His capture verification using electro-mechanical delay |
US20130123872A1 (en) * | 2011-11-03 | 2013-05-16 | Pacesetter, Inc. | Leadless implantable medical device with dual chamber sensing functionality |
WO2013074787A1 (en) | 2011-11-16 | 2013-05-23 | Cardiac Pacemakers, Inc. | Electrograms to identify bundle branch block morphology |
US9734304B2 (en) | 2011-12-02 | 2017-08-15 | Lumiradx Uk Ltd | Versatile sensors with data fusion functionality |
US9700222B2 (en) | 2011-12-02 | 2017-07-11 | Lumiradx Uk Ltd | Health-monitor patch |
US9168382B2 (en) * | 2012-10-11 | 2015-10-27 | Cardiac Pacemakers, Inc. | Method and apparatus for selective his bundle pacing |
US10773076B2 (en) | 2016-07-05 | 2020-09-15 | Wesley Robert Pedersen | Temporary pacing lead |
US9999775B2 (en) * | 2016-07-29 | 2018-06-19 | Medtronic, Inc. | System and method for controlling cardiac pacing mode switching |
WO2018089311A1 (en) | 2016-11-08 | 2018-05-17 | Cardiac Pacemakers, Inc | Implantable medical device for atrial deployment |
US10493284B2 (en) | 2017-03-30 | 2019-12-03 | Newstim, Inc. | System for treating Brugada syndrome |
US10335600B2 (en) | 2017-03-30 | 2019-07-02 | Newstim, Inc. | Cardiac device for treating Brugada syndrome |
US10765875B2 (en) | 2017-05-04 | 2020-09-08 | University Of Utah Research Foundation | Implantable cardiac devices and methods for delivering low energy, pain-free defibrillation signals for ventricular arrhythmias |
US10799703B2 (en) * | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
WO2019195282A1 (en) | 2018-04-02 | 2019-10-10 | Cardiac Pacemakers Inc | Bundle of his lead delivery catheter, system and method |
US10786170B2 (en) * | 2018-06-26 | 2020-09-29 | General Electric Company | Electrophysiology data acquisition system and method with differentiated equalization drive circuits |
US11000689B2 (en) | 2018-07-15 | 2021-05-11 | Eagle Point Medical LLC | Leadless multi-electrode cardiac pacemakers and methods of implantation thereof |
US10729902B1 (en) | 2018-07-15 | 2020-08-04 | Eagle Point Medical LLC | Intraseptal multi-electrode cardiac pacemaker and methods of use thereof |
US10406370B1 (en) | 2018-07-15 | 2019-09-10 | Eagle Point Medical LLC | Single conduit multi-electrode cardiac pacemaker and methods of using thereof |
US10695558B2 (en) | 2018-07-15 | 2020-06-30 | Eagle Point Medical LLC | Single conduit multi-electrode cardiac pacemaker and methods of using thereof |
KR102167091B1 (en) * | 2018-08-21 | 2020-10-16 | (주) 타우피엔유메디칼 | Electrophysiology catheter including Snare |
US11648397B1 (en) | 2018-10-12 | 2023-05-16 | Vincent Gaudiani | Transcoronary sinus pacing of posteroseptal left ventricular base |
US11577075B1 (en) | 2018-10-12 | 2023-02-14 | Vincent A. Gaudiani | Transcoronary sinus pacing of his bundle |
US20230355988A1 (en) * | 2020-08-17 | 2023-11-09 | Expanse Technology Partners, LLC | Transvenous pacing system |
WO2022066273A1 (en) * | 2020-09-23 | 2022-03-31 | Mower Morton M | Cardiac pacing via the distal purkinje system with ultra-short pulse widths |
CN113740400B (en) * | 2021-08-18 | 2023-10-24 | 淮阴工学院 | Analysis and detection device of closed bipolar electrode array with symmetrical reference electrode |
CN115738069B (en) * | 2022-11-21 | 2023-11-10 | 河南省贝威科技有限公司 | Device for cardiac electrical stimulation |
Family Cites Families (387)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3614955A (en) | 1970-02-09 | 1971-10-26 | Medtronic Inc | Standby defibrillator and method of operation |
US3942536A (en) * | 1971-03-15 | 1976-03-09 | Mieczyslaw Mirowski | Cardioverting device having single intravascular catheter electrode system and method for its use |
US3804098A (en) * | 1972-04-17 | 1974-04-16 | Medronic Inc | Body implantable lead |
US3866615A (en) * | 1973-01-15 | 1975-02-18 | Daigle Claude W | Portable electronic cardiac stimulator |
DE2319054C3 (en) | 1973-04-14 | 1980-03-06 | Hans Dr.Med. Stockholm Lagergren | Electrode arrangement |
US3949757A (en) * | 1974-05-13 | 1976-04-13 | Sabel George H | Catheter for atrio-ventricular pacemaker |
US3995623A (en) | 1974-12-23 | 1976-12-07 | American Hospital Supply Corporation | Multipurpose flow-directed catheter |
US4026303A (en) * | 1975-11-17 | 1977-05-31 | Vitatron Medical B.V. | Endocardial pacing electrode |
US4030508A (en) | 1976-02-04 | 1977-06-21 | Vitatron Medical B.V. | Low output electrode for cardiac pacing |
US4057067A (en) | 1976-04-06 | 1977-11-08 | Lajos Thomas Z | Atrioventricular electrode |
US4278093A (en) | 1976-06-08 | 1981-07-14 | American Technology, Inc. | Interchangeable pacemaker connector for leads |
US4106512A (en) | 1976-12-16 | 1978-08-15 | Medtronic, Inc. | Transvenously implantable lead |
US4154247A (en) * | 1977-04-01 | 1979-05-15 | Medtronic, Inc. | Formable cardiac pacer lead and method of assembly and attachment to a body organ |
US4217913A (en) | 1977-10-10 | 1980-08-19 | Medtronic, Inc. | Body-implantable lead with protected, extendable tissue securing means |
US4156429A (en) | 1977-10-11 | 1979-05-29 | Cardiac Pacemakers, Inc. | Implantable electrode |
US4136703A (en) * | 1978-03-09 | 1979-01-30 | Vitatron Medical B.V. | Atrial lead and method of inserting same |
US4282885A (en) | 1978-08-21 | 1981-08-11 | Bisping Hans Juergen | Electrode for implantation in the heart |
US4289134A (en) * | 1979-07-23 | 1981-09-15 | Electro-Catheter Corporation | Tripolar catheter apparatus |
US4458677A (en) | 1979-09-19 | 1984-07-10 | Mccorkle Jr Charles E | Intravenous channel cardiac electrode and lead assembly and method |
US4332259A (en) | 1979-09-19 | 1982-06-01 | Mccorkle Jr Charles E | Intravenous channel cardiac electrode and lead assembly and method |
US4258725A (en) * | 1979-09-21 | 1981-03-31 | Medtronic, Inc. | Pacing lead with stylet and tapered terminal pin |
US4289144A (en) | 1980-01-10 | 1981-09-15 | Medtronic, Inc. | A-V Sidearm lead |
US4365639A (en) | 1980-02-07 | 1982-12-28 | Applied Cardiac Electrophysiology | Catheter, cardiac pacemaker and method of pacing |
IT1147750B (en) | 1980-06-19 | 1986-11-26 | Sorin Biomedica Spa | ELECTRODE FOR CARDIAC STIMULATORS |
US4311153A (en) * | 1980-09-30 | 1982-01-19 | Medtronic, Inc. | Screw-in lead having lead tip with membrane |
US4393883A (en) | 1980-11-03 | 1983-07-19 | Medtronic, Inc. | Single pass A-V lead |
US4643201A (en) * | 1981-02-02 | 1987-02-17 | Medtronic, Inc. | Single-pass A-V lead |
CA1173114A (en) | 1981-02-02 | 1984-08-21 | David F. Juncker | Body implantable lead with improved dcd electrode |
US4497326A (en) * | 1981-04-06 | 1985-02-05 | Curry Paul V L | Heart pacing lead |
US4402329A (en) | 1981-09-28 | 1983-09-06 | Medtronic, Inc. | Positive anchoring A-V lead |
US4458695A (en) | 1982-07-16 | 1984-07-10 | Cordis Corporation | Multipolar electrode assembly for pacing lead |
US4469104A (en) | 1982-07-16 | 1984-09-04 | Cordis Corporation | Multipolar connector for pacing lead |
US4437474A (en) * | 1982-07-16 | 1984-03-20 | Cordis Corporation | Method for making multiconductor coil and the coil made thereby |
US4463765A (en) | 1982-08-30 | 1984-08-07 | Cordis Corporation | Screw-in pacing lead assembly |
US4559951A (en) | 1982-11-29 | 1985-12-24 | Cardiac Pacemakers, Inc. | Catheter assembly |
US4602645A (en) | 1982-12-16 | 1986-07-29 | C. R. Bard, Inc. | Atrio-ventricular pacing catheter |
JPS59178456A (en) * | 1983-03-30 | 1984-10-09 | Fuji Photo Film Co Ltd | Color image forming method |
US4540236A (en) | 1983-07-18 | 1985-09-10 | Cordis Corporation | Quick lock/quick release connector |
US4549548A (en) | 1983-09-14 | 1985-10-29 | Vitafin N.V. | Pacemaker system with automatic event-programmed switching between unipolar and bipolar operation |
US4570642A (en) * | 1983-09-23 | 1986-02-18 | Daig Corporation | Endocardial extendable screw-in lead |
US4567901A (en) * | 1983-12-15 | 1986-02-04 | Cordis Corporation | Prebent ventricular/atrial cardiac pacing lead |
US4627439A (en) | 1983-12-15 | 1986-12-09 | Cordis Corporation | Prebent ventricular/atrial cardiac pacing lead |
US4624266A (en) | 1983-12-19 | 1986-11-25 | Daig Corporation | Introducer tool for screw-in lead |
US4630204A (en) | 1984-02-21 | 1986-12-16 | Mortara Instrument Inc. | High resolution ECG waveform processor |
DE3412950A1 (en) * | 1984-04-06 | 1985-10-17 | Peter Dr.-Ing. 7889 Grenzach-Wyhlen Osypka | SURGICAL ELECTRODE |
US4892102A (en) | 1984-04-16 | 1990-01-09 | Astrinsky Eliezer A | Cardiac pacing and/or sensing lead and method of use |
US4819647A (en) * | 1984-05-03 | 1989-04-11 | The Regents Of The University Of California | Intracochlear electrode array |
US4603705A (en) | 1984-05-04 | 1986-08-05 | Mieczyslaw Mirowski | Intravascular multiple electrode unitary catheter |
US4577643A (en) * | 1984-05-10 | 1986-03-25 | Cordis Corporation | Movable multi-contact electromechanical connection |
US4543956A (en) | 1984-05-24 | 1985-10-01 | Cordis Corporation | Biphasic cardiac pacer |
US4664113A (en) * | 1984-05-30 | 1987-05-12 | Advanced Cardiovascular Systems, Inc. | Steerable dilatation catheter with rotation limiting device |
US4589420A (en) | 1984-07-13 | 1986-05-20 | Spacelabs Inc. | Method and apparatus for ECG rhythm analysis |
FR2575925B1 (en) | 1985-01-16 | 1988-12-09 | Roudy Gil | ELECTRODE FOR HEART STIMULATION AND DETECTION PROBE |
US4649937A (en) * | 1985-01-28 | 1987-03-17 | Cordis Corporation | Etched grooved electrode for pacing lead and method for making same |
USH356H (en) | 1985-02-27 | 1987-11-03 | Medtronic, Inc. | Epicardial lead having low threshold, low polarization myocardial electrode |
US4649938A (en) * | 1985-04-29 | 1987-03-17 | Mcarthur William A | Tissue-stimulating electrode having sealed, low-friction extendable/retractable active fixation means |
US4667686A (en) * | 1985-05-16 | 1987-05-26 | Cordis Corporation | Pacer lead terminal assembly |
US4624265A (en) | 1985-07-24 | 1986-11-25 | Ge. Sv. In. S.R.L. | Electro-catheter used in physiological cardiac stimulation simulative of the auriculo-ventricular sequence, featuring active engagement of the cardiac muscle |
US4646755A (en) * | 1985-10-21 | 1987-03-03 | Daig Corporation | Introducer tool for endocardial screw-in lead |
US4785815A (en) | 1985-10-23 | 1988-11-22 | Cordis Corporation | Apparatus for locating and ablating cardiac conduction pathways |
US4641649A (en) * | 1985-10-30 | 1987-02-10 | Rca Corporation | Method and apparatus for high frequency catheter ablation |
US4895152A (en) * | 1985-12-11 | 1990-01-23 | Telectronics N.V. | System for cardiac pacing |
US4721115A (en) * | 1986-02-27 | 1988-01-26 | Cardiac Pacemakers, Inc. | Diagnostic catheter for monitoring cardiac output |
US4751931A (en) | 1986-09-22 | 1988-06-21 | Allegheny-Singer Research Institute | Method and apparatus for determining his-purkinje activity |
US4784161A (en) | 1986-11-24 | 1988-11-15 | Telectronics, N.V. | Porous pacemaker electrode tip using a porous substrate |
US4799486A (en) * | 1987-03-13 | 1989-01-24 | Cardiac Pacemakers, Inc. | Refractoriless atrial sensing in dual chamber pacemakers |
DE3708133A1 (en) | 1987-03-13 | 1988-09-22 | Bisping Hans Juergen | IMPLANTABLE ELECTRODE PROBE WITH EXTENDABLE SCREW ELECTRODE |
US4799493A (en) * | 1987-03-13 | 1989-01-24 | Cardiac Pacemakers, Inc. | Dual channel coherent fibrillation detection system |
DE3712082A1 (en) | 1987-04-09 | 1988-10-20 | Bisping Hans Juergen | Implantable electrode probe with extendable and retractable screwing electrode |
US4876109A (en) | 1987-04-13 | 1989-10-24 | Cardiac Pacemakers, Inc. | Soluble covering for cardiac pacing electrode |
US4819662A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Cardiac electrode with drug delivery capabilities |
US4819661A (en) * | 1987-10-26 | 1989-04-11 | Cardiac Pacemakers, Inc. | Positive fixation cardiac electrode with drug elution capabilities |
EP0321764A1 (en) | 1987-12-23 | 1989-06-28 | Siemens-Elema AB | Method and means for detecting events in a signal |
US4922927A (en) * | 1987-12-30 | 1990-05-08 | Intermedics, Inc. | Transvenous defibrillating and pacing lead |
US5092879A (en) * | 1988-02-17 | 1992-03-03 | Jarvik Robert K | Intraventricular artificial hearts and methods of their surgical implantation and use |
US4994078A (en) * | 1988-02-17 | 1991-02-19 | Jarvik Robert K | Intraventricular artificial hearts and methods of their surgical implantation and use |
US4922607A (en) * | 1988-05-25 | 1990-05-08 | Medtronic, Inc. | Method of fabrication an in-line, multipolar electrical connector |
US5016646A (en) * | 1988-11-29 | 1991-05-21 | Telectronics, N.V. | Thin electrode lead and connections |
US4924881A (en) * | 1989-05-12 | 1990-05-15 | Intermedics, Inc. | Implantable endocardial lead with fixation device retractable by threaded stylet |
US4967766A (en) | 1989-05-16 | 1990-11-06 | Intermedics, Inc. | Implantable endocardial lead with fixation apparatus retractable by a lanyard |
US5050001A (en) | 1989-07-07 | 1991-09-17 | Fuji Photo Film Co., Ltd. | Printing system with liquid crystal shutter matrix panel |
US5002067A (en) * | 1989-08-23 | 1991-03-26 | Medtronic, Inc. | Medical electrical lead employing improved penetrating electrode |
US4953564A (en) | 1989-08-23 | 1990-09-04 | Medtronic, Inc. | Screw-in drug eluting lead |
US4972848A (en) | 1989-08-23 | 1990-11-27 | Medtronic, Inc. | Medical electrical lead with polymeric monolithic controlled release device and method of manufacture |
US4987897A (en) | 1989-09-18 | 1991-01-29 | Medtronic, Inc. | Body bus medical device communication system |
US5063932A (en) | 1989-10-03 | 1991-11-12 | Mieczyslaw Mirowski | Controlled discharge defibrillation electrode |
US5036848A (en) | 1989-10-16 | 1991-08-06 | Brunswick Biomedical Technologies, Inc. | Method and apparatus for controlling breathing employing internal and external electrodes |
US5255693A (en) | 1989-11-02 | 1993-10-26 | Possis Medical, Inc. | Cardiac lead |
US5056516A (en) | 1989-11-02 | 1991-10-15 | Intermedics, Inc. | Implantable endocordial lead with torque-transmitting lanyard |
US5007864A (en) * | 1989-11-27 | 1991-04-16 | Siemens-Pacesetter, Inc. | Device for adapting a pacemaker lead to a pacemaker |
US5076285A (en) | 1990-03-30 | 1991-12-31 | Medtronic, Inc. | Screw-in lead |
IT1238542B (en) | 1990-04-05 | 1993-08-18 | Enzo Borghi | THREE-POLE RETRACTABLE LEAD WITH ENDOCAVITARY ANCHORAGE ACTIVE FOR CARDIAC STIMULATION. |
US5275620A (en) * | 1990-05-21 | 1994-01-04 | Telectronics, N.V. | Implantable lead connectors and remote lead assembly |
US5050601A (en) | 1990-05-29 | 1991-09-24 | Joel Kupersmith | Cardiac defibrillator electrode arrangement |
US5083564A (en) | 1990-06-01 | 1992-01-28 | Board Of Regents Of The University Of Oklahoma | Method for alleviating and diagnosing symptoms of heart block |
US5320642A (en) | 1990-06-01 | 1994-06-14 | Board Of Regents For The University Of Ok | Method for alleviating and diagnosing symptoms of heart block |
US5370665A (en) | 1990-08-10 | 1994-12-06 | Medtronic, Inc. | Medical stimulator with multiple operational amplifier output stimulation circuits |
US5174289A (en) * | 1990-09-07 | 1992-12-29 | Cohen Fred M | Pacing systems and methods for control of the ventricular activation sequence |
US5267560A (en) | 1990-09-07 | 1993-12-07 | Cohen Fred M | Methods for control of the ventricular activation sequence |
US5282845A (en) * | 1990-10-01 | 1994-02-01 | Ventritex, Inc. | Multiple electrode deployable lead |
US5129404A (en) | 1990-12-21 | 1992-07-14 | Intermedics, Inc. | Implantable endocardial lead with retractable fixation apparatus |
FR2671010B1 (en) | 1990-12-27 | 1993-07-09 | Ela Medical Sa | ENDOCARDIAC PROBE PROVIDED WITH AN ACTIVE FIXING MEMBER |
US5476497A (en) | 1991-01-09 | 1995-12-19 | Ann Mirowski | Oval electrode lead body |
US5242430A (en) | 1991-01-17 | 1993-09-07 | Cordis Corporation | Limited turn handle for catheter |
US5144960A (en) | 1991-03-20 | 1992-09-08 | Medtronic, Inc. | Transvenous defibrillation lead and method of use |
EP0588988A4 (en) | 1991-04-10 | 1996-08-07 | British Tech Group Usa | Defibrillator and demand pacer catheter and method |
US5152299A (en) | 1991-04-19 | 1992-10-06 | Intermedics, Inc. | Implantable endocardial lead with spring-loaded screw-in fixation apparatus |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US6144879A (en) | 1991-05-17 | 2000-11-07 | Gray; Noel Desmond | Heart pacemaker |
US5267564A (en) * | 1991-06-14 | 1993-12-07 | Siemens Pacesetter, Inc. | Pacemaker lead for sensing a physiologic parameter of the body |
US5179962A (en) * | 1991-06-20 | 1993-01-19 | Possis Medical, Inc. | Cardiac lead with retractible fixators |
US5416510A (en) * | 1991-08-28 | 1995-05-16 | Stereographics Corporation | Camera controller for stereoscopic video system |
US5181511A (en) * | 1991-10-21 | 1993-01-26 | Telectronics Pacing Systems, Inc. | Apparatus and method for antitachycardia pacing using a virtual electrode |
US5524338A (en) * | 1991-10-22 | 1996-06-11 | Pi Medical Corporation | Method of making implantable microelectrode |
US5324327A (en) | 1991-12-17 | 1994-06-28 | Cohen Donald M | Low threshold cardiac pacing lead |
US5313953A (en) | 1992-01-14 | 1994-05-24 | Incontrol, Inc. | Implantable cardiac patient monitor |
US5259395A (en) | 1992-01-15 | 1993-11-09 | Siemens Pacesetter, Inc. | Pacemaker lead with extendable retractable lockable fixing helix |
US5223226A (en) | 1992-04-14 | 1993-06-29 | Millipore Corporation | Insulated needle for forming an electrospray |
DE69321030T3 (en) * | 1992-05-25 | 2006-07-13 | St. Jude Medical Ab | Device for stimulating the heart |
US5318572A (en) | 1992-06-02 | 1994-06-07 | Siemens Pacesetter, Inc. | High efficiency tissue stimulating and signal sensing electrode |
US5336252A (en) | 1992-06-22 | 1994-08-09 | Cohen Donald M | System and method for implanting cardiac electrical leads |
US5447533A (en) | 1992-09-03 | 1995-09-05 | Pacesetter, Inc. | Implantable stimulation lead having an advanceable therapeutic drug delivery system |
FR2696348B1 (en) | 1992-10-01 | 1994-12-09 | Dev Et | Electrode for a retractable biological screw cardiac stimulation device. |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
US5344439A (en) | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Catheter with retractable anchor mechanism |
US5807306A (en) | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US5814077A (en) | 1992-11-13 | 1998-09-29 | Pacesetter, Inc. | Pacemaker and method of operating same that provides functional atrial cardiac pacing with ventricular support |
JPH06205842A (en) | 1992-12-04 | 1994-07-26 | Siemens Ag | Lead assembly for implantable medical device |
US5358516A (en) | 1992-12-11 | 1994-10-25 | W. L. Gore & Associates, Inc. | Implantable electrophysiology lead and method of making |
US5300108A (en) * | 1993-01-05 | 1994-04-05 | Telectronics Pacing Systems, Inc. | Active fixation lead with a dual-pitch, free spinning compound screw |
US5439391A (en) | 1993-02-09 | 1995-08-08 | Ventritex, Inc. | Lead adapter |
SE9300469D0 (en) | 1993-02-12 | 1993-02-12 | Siemens Elema Ab | The electrode device |
EP0612538A3 (en) | 1993-02-22 | 1995-04-05 | Cardiac Pacemakers Inc | Metallized, implantable cardiac electrode. |
US5374286A (en) | 1993-03-31 | 1994-12-20 | Medtronic, Inc. | Torque indicator for fixed screw leads |
US5366496A (en) | 1993-04-01 | 1994-11-22 | Cardiac Pacemakers, Inc. | Subcutaneous shunted coil electrode |
US5354327A (en) | 1993-04-07 | 1994-10-11 | Medtronic, Inc. | Conductor coil with specific ratio of torque to bending stiffness |
US5466253A (en) | 1993-04-27 | 1995-11-14 | Pacesetter, Inc. | Crush resistant multi-conductor lead body |
US5408744A (en) | 1993-04-30 | 1995-04-25 | Medtronic, Inc. | Substrate for a sintered electrode |
US5381790A (en) * | 1993-06-23 | 1995-01-17 | Kanesaka; Nozomu | Electrophysiology apparatus |
US5342414A (en) | 1993-07-01 | 1994-08-30 | Medtronic, Inc. | Transvenous defibrillation lead |
US5431681A (en) | 1993-09-22 | 1995-07-11 | Pacesetter, Inc. | Combination pacing and defibrillating lead having sensing capability |
US5433735A (en) | 1993-09-27 | 1995-07-18 | Zanakis; Michael F. | Electrical stimulation technique for tissue regeneration |
US5456708A (en) | 1993-10-28 | 1995-10-10 | Pacesetter, Inc. | Rotatable pin, screw-in pacing and sensing lead having improved tip and fluidic seal |
US5411544A (en) * | 1993-11-02 | 1995-05-02 | Ventritex, Inc. | Defibrillation lead with improved mechanical and electrical characteristics |
EP0651974B1 (en) | 1993-11-10 | 2000-05-03 | Xomed, Inc. | Bipolar electrosurgical instrument and method for making the instrument |
US5393929A (en) * | 1993-11-23 | 1995-02-28 | Junkosha Co. Ltd. | Electrical insulation and articles thereof |
SE9304031D0 (en) | 1993-12-03 | 1993-12-03 | Siemens Elema Ab | electrode System |
US5492119A (en) * | 1993-12-22 | 1996-02-20 | Heart Rhythm Technologies, Inc. | Catheter tip stabilizing apparatus |
US5456706A (en) | 1994-01-04 | 1995-10-10 | Ventritex, Inc. | Cardiac defibrillation lead having defibrillation and atrial sensing electrodes |
ITRM940130A1 (en) | 1994-03-10 | 1995-09-11 | P A & M Spa | SAFETY ELEMENT TO GUARANTEE THE ELECTRICAL RELIABILITY OF THE ELECTRODOCATHETERS FOR THE ELECTRIC STIMULATION OF THE |
US5500008A (en) * | 1994-03-29 | 1996-03-19 | Ventritex, Inc. | Method and apparatus for delivering defibrillation shocks with improved effectiveness |
US5476501A (en) | 1994-05-06 | 1995-12-19 | Medtronic, Inc. | Silicon insulated extendable/retractable screw-in pacing lead with high efficiency torque transfer |
US5593405A (en) * | 1994-07-16 | 1997-01-14 | Osypka; Peter | Fiber optic endoscope |
US5522875A (en) | 1994-07-28 | 1996-06-04 | Medtronic, Inc. | Medical electrical lead system having a torque transfer stylet |
US5522874A (en) | 1994-07-28 | 1996-06-04 | Gates; James T. | Medical lead having segmented electrode |
US5527344A (en) | 1994-08-01 | 1996-06-18 | Illinois Institute Of Technology | Pharmacologic atrial defibrillator and method |
US5514172A (en) * | 1994-08-31 | 1996-05-07 | Pacesetter, Inc. | Multi-conductor lead including a connector with an interlocking insulator |
US5628778A (en) | 1994-11-21 | 1997-05-13 | Medtronic Inc. | Single pass medical electrical lead |
US5593433A (en) * | 1994-12-19 | 1997-01-14 | Intermedics, Inc. | Implantable endocardial lead with self-healing retractable fixation apparatus |
US5545201A (en) | 1995-03-29 | 1996-08-13 | Pacesetter, Inc. | Bipolar active fixation lead for sensing and pacing the heart |
US5634829A (en) | 1995-04-20 | 1997-06-03 | Interlock Corporation | Low engagement force terminal with easy off-axis disengagement |
US5609158A (en) | 1995-05-01 | 1997-03-11 | Arrhythmia Research Technology, Inc. | Apparatus and method for predicting cardiac arrhythmia by detection of micropotentials and analysis of all ECG segments and intervals |
AU5558096A (en) | 1995-05-01 | 1996-11-21 | Medtronic Cardiorhythm | Dual curve ablation catheter and method |
US5578068A (en) | 1995-05-08 | 1996-11-26 | Medtronic, Inc. | Medical electrical lead with radially asymmetric tip |
US5674272A (en) | 1995-06-05 | 1997-10-07 | Ventritex, Inc. | Crush resistant implantable lead |
EP0769866A3 (en) | 1995-10-19 | 2001-02-07 | Ncr International Inc. | Automated voice mail/answering machine greeting system |
US5709753A (en) * | 1995-10-27 | 1998-01-20 | Specialty Coating Sysetms, Inc. | Parylene deposition apparatus including a heated and cooled dimer crucible |
US5733323A (en) | 1995-11-13 | 1998-03-31 | Cordis Corporation | Electrically conductive unipolar vascular sheath |
US5674274A (en) | 1995-12-14 | 1997-10-07 | Pacesetter, Inc. | Implantable adjustable single-pass A-V lead for use with an implantable stimulation device |
US5683447A (en) | 1995-12-19 | 1997-11-04 | Ventritex, Inc. | Lead with septal defibrillation and pacing electrodes |
EP0871512A1 (en) | 1995-12-22 | 1998-10-21 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
US5681013A (en) | 1995-12-26 | 1997-10-28 | The Boeing Company | Vortex leading edge flap assembly for supersonic airplanes |
US5766042A (en) | 1995-12-28 | 1998-06-16 | Medtronic, Inc. | Tool-less locking and sealing assembly for implantable medical device |
IL119261A0 (en) | 1996-09-17 | 1996-12-05 | New Technologies Sa Ysy Ltd | Electrical muscle controller |
ATE375070T1 (en) * | 1996-01-31 | 2007-10-15 | Cochlear Ltd | THIN FILM PRODUCTION TECHNOLOGY FOR IMPLANTABLE ELECTRODES |
US5772693A (en) | 1996-02-09 | 1998-06-30 | Cardiac Control Systems, Inc. | Single preformed catheter configuration for a dual-chamber pacemaker system |
DE19609471A1 (en) * | 1996-03-01 | 1997-11-13 | Biotronik Mess & Therapieg | Electrode arrangement |
US5908392A (en) | 1996-03-13 | 1999-06-01 | Pacesetter, Inc. | System and method for recording and storing medical data in response to a programmable trigger |
US5702427A (en) | 1996-03-28 | 1997-12-30 | Medtronic, Inc. | Verification of capture using pressure waves transmitted through a pacing lead |
US5628779A (en) | 1996-04-03 | 1997-05-13 | Pacesetter, Inc. | Single-pass A-V pacing lead |
US5683445A (en) | 1996-04-29 | 1997-11-04 | Swoyer; John M. | Medical electrical lead |
US5728140A (en) | 1996-06-17 | 1998-03-17 | Cardiac Pacemakers, Inc. | Method for evoking capture of left ventricle using transeptal pacing lead |
US5800465A (en) * | 1996-06-18 | 1998-09-01 | Medtronic, Inc. | System and method for multisite steering of cardiac stimuli |
US5944710A (en) | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
US5716390A (en) * | 1996-08-09 | 1998-02-10 | Pacesetter, Inc. | Reduced diameter active fixation pacing lead using concentric interleaved coils |
US5871506A (en) | 1996-08-19 | 1999-02-16 | Mower; Morton M. | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
US6341235B1 (en) | 1996-08-19 | 2002-01-22 | Mower Chf Treatment Irrevocable Trust | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
US7440800B2 (en) | 1996-08-19 | 2008-10-21 | Mr3 Medical, Llc | System and method for managing detrimental cardiac remodeling |
AUPO178196A0 (en) * | 1996-08-20 | 1996-09-12 | Telefonaktiebolaget Lm Ericsson (Publ) | Voice announcement management system |
US5810887A (en) | 1996-08-23 | 1998-09-22 | Rhythm Technologies, Inc. | Temporary catheter |
US5800464A (en) | 1996-10-03 | 1998-09-01 | Medtronic, Inc. | System for providing hyperpolarization of cardiac to enhance cardiac function |
US5814079A (en) | 1996-10-04 | 1998-09-29 | Medtronic, Inc. | Cardiac arrhythmia management by application of adnodal stimulation for hyperpolarization of myocardial cells |
US5878431A (en) * | 1996-10-04 | 1999-03-02 | Hewlett-Packard Company | Method and apparatus for providing topology based enterprise management services |
US5782898A (en) | 1996-10-15 | 1998-07-21 | Angeion Corporation | System for anchoring mid-lead electrode on an endocardial catheter lead |
US6059726A (en) | 1996-11-08 | 2000-05-09 | The Regents Of The University Of California | Method for locating the atrio-ventricular (AV) junction of the heart and injecting active substances therein |
US5718720A (en) * | 1996-12-13 | 1998-02-17 | Sulzer Intermedics Inc. | Implantable cardiac stimulator with capture detection and impedance based autotuning of capture detection |
DE19654491A1 (en) * | 1996-12-17 | 1998-06-18 | Biotronik Mess & Therapieg | Stimulation electrode arrangement |
EP0971767A2 (en) | 1996-12-19 | 2000-01-19 | Medtronic, Inc. | Medical electrical lead |
FR2757773B1 (en) | 1996-12-27 | 1999-07-16 | Ela Medical Sa | PROBE FOR MEDICAL DEVICE TO BE IMPLANTED IN THE HUMAN HEART FOR THE STIMULATION AND THE AURICULAR AND VENTRICULAR DETECTION OF THE HEART |
US5871529A (en) * | 1997-01-16 | 1999-02-16 | Cardiac Pacemakers, Inc. | Electrode for high impedance heart stimulation |
US5755766A (en) * | 1997-01-24 | 1998-05-26 | Cardiac Pacemakers, Inc. | Open-ended intravenous cardiac lead |
US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
US6547787B1 (en) * | 1997-03-13 | 2003-04-15 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US5861013A (en) * | 1997-04-29 | 1999-01-19 | Medtronic Inc. | Peak tracking capture detection circuit and method |
US5971983A (en) * | 1997-05-09 | 1999-10-26 | The Regents Of The University Of California | Tissue ablation device and method of use |
US5769881A (en) | 1997-05-22 | 1998-06-23 | Sulzer Intermedics Inc. | Endocardial lead with multiple branches |
US5876399A (en) | 1997-05-28 | 1999-03-02 | Irvine Biomedical, Inc. | Catheter system and methods thereof |
US5876431A (en) * | 1997-07-30 | 1999-03-02 | Sulzer Intermedics Inc. | Small cable endocardial lead with exposed guide tube |
US5851227A (en) | 1997-07-30 | 1998-12-22 | Sulzer Intermedics Inc. | Cardiac pacemaker cable lead |
US6024739A (en) * | 1997-09-05 | 2000-02-15 | Cordis Webster, Inc. | Method for detecting and revascularizing ischemic myocardial tissue |
US5871531A (en) | 1997-09-25 | 1999-02-16 | Medtronic, Inc. | Medical electrical lead having tapered spiral fixation |
US20020120200A1 (en) | 1997-10-14 | 2002-08-29 | Brian Brockway | Devices, systems and methods for endocardial pressure measurement |
US6007476A (en) | 1997-10-22 | 1999-12-28 | Emf Therapeutics, Inc. | Non-particle, non-photonic device and method for affecting angiogenesis |
US5995871A (en) * | 1997-10-29 | 1999-11-30 | Uab Research Foundation | System and method for cardioversion using scan stimulation |
US6070104A (en) | 1997-11-28 | 2000-05-30 | Medtronic, Inc. | Medical electrical right atrium and coronary sinus lead |
US6212434B1 (en) * | 1998-07-22 | 2001-04-03 | Cardiac Pacemakers, Inc. | Single pass lead system |
US6152954A (en) * | 1998-07-22 | 2000-11-28 | Cardiac Pacemakers, Inc. | Single pass lead having retractable, actively attached electrode for pacing and sensing |
US6141594A (en) * | 1998-07-22 | 2000-10-31 | Cardiac Pacemakers, Inc. | Single pass lead and system with active and passive fixation elements |
US20030113303A1 (en) | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
US20030125615A1 (en) | 1998-02-05 | 2003-07-03 | Yitzhack Schwartz | Homing of autologous cells to a target zone in tissue using active therapeutics or substances |
ES2293473T3 (en) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | INTRACARDIAC ADMINISTRATION OF FARMACO. |
US20030129750A1 (en) | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US5964795A (en) | 1998-03-13 | 1999-10-12 | Medtronic, Inc. | Medical electrical lead |
US20010044619A1 (en) | 1998-04-08 | 2001-11-22 | Peter A. Altman | Cardiac drug delivery system and method for use |
US6256541B1 (en) | 1998-04-17 | 2001-07-03 | Cardiac Pacemakers, Inc. | Endocardial lead having defibrillation and sensing electrodes with septal anchoring |
US6144880A (en) * | 1998-05-08 | 2000-11-07 | Cardiac Pacemakers, Inc. | Cardiac pacing using adjustable atrio-ventricular delays |
EP1079890A4 (en) | 1998-05-08 | 2008-12-03 | Genetronics Inc | Electrically induced vessel vasodilation |
US6165164A (en) | 1999-03-29 | 2000-12-26 | Cordis Corporation | Catheter for injecting therapeutic and diagnostic agents |
US6623473B1 (en) | 1998-06-04 | 2003-09-23 | Biosense Webster, Inc. | Injection catheter with multi-directional delivery injection needle |
US6575931B1 (en) | 1998-06-04 | 2003-06-10 | Biosense Webster, Inc. | Catheter with injection needle |
US6905476B2 (en) | 1998-06-04 | 2005-06-14 | Biosense Webster, Inc. | Catheter with injection needle |
US6540725B1 (en) * | 1998-06-04 | 2003-04-01 | Biosense Webster, Inc. | Injection catheter with controllably extendable injection needle |
US7416547B2 (en) | 1999-03-29 | 2008-08-26 | Biosense Webster Inc. | Injection catheter |
US6623474B1 (en) | 1998-06-04 | 2003-09-23 | Biosense Webster, Inc. | Injection catheter with needle stop |
US6463334B1 (en) | 1998-11-02 | 2002-10-08 | Cardiac Pacemakers, Inc. | Extendable and retractable lead |
US6501990B1 (en) * | 1999-12-23 | 2002-12-31 | Cardiac Pacemakers, Inc. | Extendable and retractable lead having a snap-fit terminal connector |
US6141588A (en) * | 1998-07-24 | 2000-10-31 | Intermedics Inc. | Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy |
US6123084A (en) | 1998-12-18 | 2000-09-26 | Eclipse Surgical Technologies, Inc. | Method for improving blood flow in the heart |
US6161029A (en) | 1999-03-08 | 2000-12-12 | Medtronic, Inc. | Apparatus and method for fixing electrodes in a blood vessel |
US6267778B1 (en) | 1999-04-12 | 2001-07-31 | Fred Michael Cohen | Pacing systems for treating functional ventricular conduction abnormalities of intrinsic origin |
US6285909B1 (en) | 1999-05-27 | 2001-09-04 | Cardiac Pacemakers, Inc. | Preserving patient specific data in implantable pulse generator systems |
WO2000074773A1 (en) | 1999-06-04 | 2000-12-14 | Impulse Dynamics N.V. | Drug delivery device |
US6526314B1 (en) | 1999-08-20 | 2003-02-25 | Cardiac Pacemakers, Inc. | Data management system for implantable cardiac device |
US6556872B2 (en) * | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6363286B1 (en) * | 1999-09-24 | 2002-03-26 | Cardiac Pacemakers, Inc. | High impedance electrode assembly |
US7062544B1 (en) | 1999-09-27 | 2006-06-13 | General Instrument Corporation | Provisioning of locally-generated prompts from a central source |
US20030093104A1 (en) | 1999-10-29 | 2003-05-15 | Bonner Matthew D. | Methods and apparatus for providing intra-pericardial access |
US20020026228A1 (en) * | 1999-11-30 | 2002-02-28 | Patrick Schauerte | Electrode for intravascular stimulation, cardioversion and/or defibrillation |
US6430441B1 (en) | 2000-01-18 | 2002-08-06 | Pacesetter, Inc. | Implantable cardiac stimulation device having autocapture/autothreshold capability |
US6650940B1 (en) | 2000-02-02 | 2003-11-18 | Cardiac Pacemakers, Inc. | Accelerometer-based heart sound detection for autocapture |
DE10011572A1 (en) | 2000-03-02 | 2001-09-06 | Biotronik Mess & Therapieg | Electrode arrangement |
US6810286B2 (en) * | 2000-03-06 | 2004-10-26 | Medtronic, Inc | Stimulation for delivery of molecular therapy |
US6585716B2 (en) * | 2000-04-05 | 2003-07-01 | Biocardia, Inc. | Method of treating the heart |
US6606517B1 (en) | 2000-04-12 | 2003-08-12 | Pacesetter, Inc. | Methods and apparatus for preventing atrial arrhythmias by overdrive pacing and prolonging atrial refractoriness using an implantable cardiac stimulation device |
EP1284781B1 (en) | 2000-05-04 | 2017-10-11 | Impulse Dynamics N.V. | Signal delivery through the right ventricular septum |
US7689437B1 (en) | 2000-06-16 | 2010-03-30 | Bodymedia, Inc. | System for monitoring health, wellness and fitness |
US6535766B1 (en) | 2000-08-26 | 2003-03-18 | Medtronic, Inc. | Implanted medical device telemetry using integrated microelectromechanical filtering |
US6584362B1 (en) | 2000-08-30 | 2003-06-24 | Cardiac Pacemakers, Inc. | Leads for pacing and/or sensing the heart from within the coronary veins |
US6544270B1 (en) * | 2000-09-14 | 2003-04-08 | Cardiac Pacemakers, Inc. | Multi-lumen cardiac catheter and system |
US6484057B2 (en) | 2000-12-21 | 2002-11-19 | Uab Research Foundation | Pacing methods and devices for treating cardiac arrhythmias and fibrillation |
US7130682B2 (en) * | 2000-12-26 | 2006-10-31 | Cardiac Pacemakers, Inc. | Pacing and sensing vectors |
WO2002053225A2 (en) * | 2000-12-29 | 2002-07-11 | Medtronic, Inc. | Electrode system for stimulating the left heart chamber |
US6445953B1 (en) * | 2001-01-16 | 2002-09-03 | Kenergy, Inc. | Wireless cardiac pacing system with vascular electrode-stents |
SE0100284D0 (en) | 2001-01-31 | 2001-01-31 | St Jude Medical | Medical communication system |
US20050203580A1 (en) * | 2001-02-13 | 2005-09-15 | Prentice John K. | Method for multiple site, right ventricular pacing with improved left ventricular function |
WO2002064205A2 (en) | 2001-02-13 | 2002-08-22 | Quetzal Biomedical, Inc. | Multi-electrode apparatus and method for treatment of congestive heart failure |
US6609027B2 (en) | 2001-02-23 | 2003-08-19 | Pacesetter, Inc. | His Bundle sensing device and associated method |
WO2002076344A1 (en) | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
WO2002087501A2 (en) | 2001-04-27 | 2002-11-07 | Quetzal Biomedical, Inc. | Improved leads for the treatment of patients with chf |
US6909920B2 (en) | 2001-04-27 | 2005-06-21 | Medtronic, Inc. | System and method for positioning an implantable medical device within a body |
US6468263B1 (en) | 2001-05-21 | 2002-10-22 | Angel Medical Systems, Inc. | Implantable responsive system for sensing and treating acute myocardial infarction and for treating stroke |
US7674245B2 (en) | 2001-06-07 | 2010-03-09 | Cardiac Pacemakers, Inc. | Method and apparatus for an adjustable shape guide catheter |
US6702744B2 (en) * | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US20020198583A1 (en) * | 2001-06-22 | 2002-12-26 | Joseph Rock | Disposable sheath providing cardiac stimulation and method |
US6804555B2 (en) | 2001-06-29 | 2004-10-12 | Medtronic, Inc. | Multi-site ventricular pacing system measuring QRS duration |
US7027876B2 (en) | 2001-10-12 | 2006-04-11 | Medtronic, Inc. | Lead system for providing electrical stimulation to the Bundle of His |
US6718206B2 (en) * | 2001-10-23 | 2004-04-06 | Medtronic, Inc. | Permanent atrial-his-ventricular sequential pacing |
US7286876B2 (en) | 2001-10-26 | 2007-10-23 | Cardiac Pacemakers, Inc. | Template-based capture verification for multi-site pacing |
US6871096B2 (en) | 2001-10-26 | 2005-03-22 | Medtronic, Inc. | System and method for bi-ventricular fusion pacing |
US6766190B2 (en) * | 2001-10-31 | 2004-07-20 | Medtronic, Inc. | Method and apparatus for developing a vectorcardiograph in an implantable medical device |
US6904316B2 (en) | 2001-11-06 | 2005-06-07 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with maximum tracking rate (MTR) hysteresis |
US7127289B2 (en) | 2001-12-05 | 2006-10-24 | Cardiac Pacemakers, Inc. | Cardiac resynchronization system employing mechanical measurement of cardiac walls |
US6768923B2 (en) | 2001-12-05 | 2004-07-27 | Cardiac Pacemakers, Inc. | Apparatus and method for ventricular pacing triggered by detection of early ventricular excitation |
US6775571B1 (en) | 2001-12-12 | 2004-08-10 | Pacesetter, Inc. | Dynamic control of overdrive pacing based on degree of randomness within heart rate |
US8391989B2 (en) | 2002-12-18 | 2013-03-05 | Cardiac Pacemakers, Inc. | Advanced patient management for defining, identifying and using predetermined health-related events |
US7039168B1 (en) | 2002-03-12 | 2006-05-02 | Bellsouth Intellectual Property Corp. | System and method for inventory of and access to recorded announcements |
US6957105B2 (en) | 2002-03-26 | 2005-10-18 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting oscillations in cardiac rhythm with electrogram signals |
US20040006265A1 (en) * | 2002-04-30 | 2004-01-08 | Karim Alhussiny | Wireless transmission-ST-segment preserved of the standard 12 leads EKG apparatus for the remote administration of thrrombolytic therapy under severe cellular channel impairment |
US7113825B2 (en) | 2002-05-03 | 2006-09-26 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting acoustic oscillations in cardiac rhythm |
US7039462B2 (en) | 2002-06-14 | 2006-05-02 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting oscillations in cardiac rhythm |
US20040247093A1 (en) | 2002-05-20 | 2004-12-09 | Potts Karl W. | System, method, and apparatus for provisioning recorded announcements |
US6978184B1 (en) | 2002-07-29 | 2005-12-20 | Marcus Frank I | Optimization method for cardiac resynchronization therapy |
US7400931B2 (en) | 2002-09-18 | 2008-07-15 | Cardiac Pacemakers, Inc. | Devices and methods to stimulate therapeutic angiogenesis for ischemia and heart failure |
US7096051B1 (en) | 2002-09-27 | 2006-08-22 | Lawrence Alder | Enhancing signals in a two-way radio system |
US6937897B2 (en) * | 2002-09-30 | 2005-08-30 | Medtronic, Inc. | Electrode for His bundle stimulation |
US7082335B2 (en) | 2002-09-30 | 2006-07-25 | Medtronic, Inc. | Multipolar pacing method and apparatus |
US6855124B1 (en) * | 2002-10-02 | 2005-02-15 | Advanced Cardiovascular Systems, Inc. | Flexible polymer needle catheter |
US7103418B2 (en) | 2002-10-02 | 2006-09-05 | Medtronic, Inc. | Active fluid delivery catheter |
CA2501732C (en) | 2002-10-09 | 2013-07-30 | Bodymedia, Inc. | Method and apparatus for auto journaling of continuous or discrete body states utilizing physiological and/or contextual parameters |
US7065405B2 (en) | 2002-11-15 | 2006-06-20 | Cardiac Pacemakers, Inc. | Stress reduction pacing mode for arrhythmia prevention |
US7317950B2 (en) | 2002-11-16 | 2008-01-08 | The Regents Of The University Of California | Cardiac stimulation system with delivery of conductive agent |
DE60209301T2 (en) | 2002-11-28 | 2006-11-02 | CSEM Centre Suisse d`Electronique et de Microtechnique S.A. - Recherche et Développement | Voltage controlled oscillator circuit for a low power electronic device |
US20040260374A1 (en) | 2002-12-19 | 2004-12-23 | Cardiac Pacemakers, Inc. | Implantable lead with fixation mechanism in the pulmonary artery |
US7127300B2 (en) | 2002-12-23 | 2006-10-24 | Cardiac Pacemakers, Inc. | Method and apparatus for enabling data communication between an implantable medical device and a patient management system |
US7395117B2 (en) | 2002-12-23 | 2008-07-01 | Cardiac Pacemakers, Inc. | Implantable medical device having long-term wireless capabilities |
US7277749B2 (en) | 2003-01-15 | 2007-10-02 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Treatments for snoring using injectable neuromuscular stimulators |
US7013176B2 (en) | 2003-01-28 | 2006-03-14 | Cardiac Pacemakers, Inc. | Method and apparatus for setting pacing parameters in cardiac resynchronization therapy |
US20040215240A1 (en) | 2003-04-11 | 2004-10-28 | Lovett Eric G. | Reconfigurable subcutaneous cardiac device |
AU2003901852A0 (en) | 2003-04-16 | 2003-05-01 | Cochlear Limited | Cochlear electrode array |
US20040213770A1 (en) | 2003-04-22 | 2004-10-28 | Endobionics, Inc. | Methods and systems for treating ischemic cardiac and other tissues |
US7558626B2 (en) | 2003-04-23 | 2009-07-07 | Medtronic, Inc. | Cardiac resynchronization via left ventricular pacing |
US8013133B2 (en) | 2003-04-25 | 2011-09-06 | Medtronic, Inc. | Genetic modification of targeted regions of the cardiac conduction system |
US20040214182A1 (en) | 2003-04-25 | 2004-10-28 | Vinod Sharma | Genetic modification of targeted regions of the cardiac conduction system |
US7330750B2 (en) | 2003-04-25 | 2008-02-12 | Instrumentarium Corp. | Estimation of cardiac death risk |
US7477932B2 (en) * | 2003-05-28 | 2009-01-13 | Cardiac Pacemakers, Inc. | Cardiac waveform template creation, maintenance and use |
JP4213522B2 (en) | 2003-05-30 | 2009-01-21 | テルモ株式会社 | Heart treatment equipment |
US7231249B2 (en) | 2003-07-24 | 2007-06-12 | Mirowski Family Ventures, L.L.C. | Methods, apparatus, and systems for multiple stimulation from a single stimulator |
US7027866B2 (en) | 2003-07-29 | 2006-04-11 | Medtronic, Inc. | Mechanically-based interval optimization for a biventricular pacing engine |
US20050049516A1 (en) | 2003-08-26 | 2005-03-03 | Ideker Raymond E. | Methods, systems and computer program products for selectively initiating interventional therapy to reduce the risk of arrhythmia |
US7184833B2 (en) * | 2003-10-07 | 2007-02-27 | Medtronic, Inc. | Multiple pacing output channels |
US7280872B1 (en) | 2003-10-16 | 2007-10-09 | Transoma Medical, Inc. | Wireless communication with implantable medical device |
US20050125041A1 (en) | 2003-11-05 | 2005-06-09 | Xiaoyi Min | Methods for ventricular pacing |
US9002452B2 (en) | 2003-11-07 | 2015-04-07 | Cardiac Pacemakers, Inc. | Electrical therapy for diastolic dysfunction |
US7319900B2 (en) * | 2003-12-11 | 2008-01-15 | Cardiac Pacemakers, Inc. | Cardiac response classification using multiple classification windows |
WO2005062823A2 (en) | 2003-12-19 | 2005-07-14 | Savacor, Inc. | Digital electrode for cardiac rhythm management |
US7245973B2 (en) | 2003-12-23 | 2007-07-17 | Cardiac Pacemakers, Inc. | His bundle mapping, pacing, and injection lead |
US7817784B2 (en) | 2003-12-23 | 2010-10-19 | Apptera, Inc. | System for managing voice files of a voice prompt server |
EP1711104B1 (en) | 2004-01-16 | 2014-03-12 | Compumedics Limited | Method and apparatus for ecg-derived sleep disordered breathing monitoring, detection and classification |
US7421292B1 (en) | 2004-02-18 | 2008-09-02 | Pacesetter, Inc. | System and method for controlling the recording of diagnostic medical data in an implantable medical device |
US7447544B1 (en) | 2004-02-18 | 2008-11-04 | Pacesetter, Inc. | System and method for controlling the recording of diagnostic medical data in an implantable medical device |
US8195304B2 (en) | 2004-06-10 | 2012-06-05 | Medtronic Urinary Solutions, Inc. | Implantable systems and methods for acquisition and processing of electrical signals |
US20060104596A1 (en) | 2004-07-02 | 2006-05-18 | Charles Askins | Deformable mirror apparatus |
US7792580B2 (en) * | 2004-09-21 | 2010-09-07 | Medtronic, Inc. | Implantable medical device with his-purkinje activity detection |
US7509170B2 (en) * | 2005-05-09 | 2009-03-24 | Cardiac Pacemakers, Inc. | Automatic capture verification using electrocardiograms sensed from multiple implanted electrodes |
US7457664B2 (en) | 2005-05-09 | 2008-11-25 | Cardiac Pacemakers, Inc. | Closed loop cardiac resynchronization therapy using cardiac activation sequence information |
US8326407B2 (en) | 2004-10-19 | 2012-12-04 | University Of Washington | Long-term monitoring for discrimination of different heart rhythms |
ATE481920T1 (en) | 2004-11-02 | 2010-10-15 | Medtronic Inc | METHOD FOR DATA RETENTION IN AN IMPLANTABLE MEDICAL DEVICE |
US7917199B2 (en) | 2004-11-02 | 2011-03-29 | Medtronic, Inc. | Patient event marking in combination with physiological signals |
US8024029B2 (en) | 2004-11-02 | 2011-09-20 | Medtronic, Inc. | Techniques for user-activated data retention in an implantable medical device |
US7412655B2 (en) | 2004-11-02 | 2008-08-12 | Yahoo! Inc. | Method and system of providing dynamic dialogs |
US20060116596A1 (en) | 2004-12-01 | 2006-06-01 | Xiaohong Zhou | Method and apparatus for detection and monitoring of T-wave alternans |
US8014861B2 (en) | 2004-12-20 | 2011-09-06 | Cardiac Pacemakers, Inc. | Systems, devices and methods relating to endocardial pacing for resynchronization |
US8326423B2 (en) | 2004-12-20 | 2012-12-04 | Cardiac Pacemakers, Inc. | Devices and methods for steering electrical stimulation in cardiac rhythm management |
US8050756B2 (en) | 2004-12-20 | 2011-11-01 | Cardiac Pacemakers, Inc. | Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management |
US8010191B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Systems, devices and methods for monitoring efficiency of pacing |
US8290586B2 (en) | 2004-12-20 | 2012-10-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device |
US8005544B2 (en) | 2004-12-20 | 2011-08-23 | Cardiac Pacemakers, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
AR047851A1 (en) | 2004-12-20 | 2006-03-01 | Giniger Alberto German | A NEW MARCAPASOS THAT RESTORES OR PRESERVES THE PHYSIOLOGICAL ELECTRIC DRIVING OF THE HEART AND A METHOD OF APPLICATION |
US8010192B2 (en) | 2004-12-20 | 2011-08-30 | Cardiac Pacemakers, Inc. | Endocardial pacing relating to conduction abnormalities |
US8423139B2 (en) | 2004-12-20 | 2013-04-16 | Cardiac Pacemakers, Inc. | Methods, devices and systems for cardiac rhythm management using an electrode arrangement |
US7321798B2 (en) | 2005-03-31 | 2008-01-22 | Medtronic, Inc. | Trans-septal/trans-myocardial ventricular pacing lead |
US7286873B2 (en) | 2005-03-31 | 2007-10-23 | Medtronic, Inc. | Method of optimizing mechanical heart rate during delivery of coupled or paired pacing |
US8538519B2 (en) | 2005-04-25 | 2013-09-17 | Cardiac Pacemakers, Inc. | Method and system for treatment of mechanical cardiac asynchrony |
JP5237089B2 (en) | 2005-05-06 | 2013-07-17 | カーディアック ペースメイカーズ, インコーポレイテッド | Controlled intermittent stress augmentation pacing |
US7366568B2 (en) | 2005-05-06 | 2008-04-29 | Cardiac Pacemakers, Inc. | Controlled delivery of intermittent stress augmentation pacing for cardioprotective effect |
US7697985B2 (en) | 2005-07-26 | 2010-04-13 | Medtronic, Inc. | System and method for providing alternative pacing modality selection |
US8838215B2 (en) | 2006-03-01 | 2014-09-16 | Angel Medical Systems, Inc. | Systems and methods of medical monitoring according to patient state |
US7702392B2 (en) | 2005-09-12 | 2010-04-20 | Ebr Systems, Inc. | Methods and apparatus for determining cardiac stimulation sites using hemodynamic data |
US7899533B2 (en) * | 2005-10-25 | 2011-03-01 | Medtronic, Inc. | System and method of AV interval selection in an implantable medical device |
US7769449B2 (en) * | 2005-10-25 | 2010-08-03 | Medtronic, Inc. | System and method of AV interval selection in an implantable medical device |
US20070129764A1 (en) * | 2005-12-06 | 2007-06-07 | Burnes John E | Method and apparatus for optimizing pacing parameters |
US20070244402A1 (en) | 2006-02-17 | 2007-10-18 | Brockway Brian P | System and method of monitoring physiological signals |
US7869871B2 (en) | 2006-03-31 | 2011-01-11 | Cardiac Pacemakers, Inc. | Pacing therapy for diastolic heart failure |
US20070232949A1 (en) | 2006-03-31 | 2007-10-04 | Ep Medsystems, Inc. | Method For Simultaneous Bi-Atrial Mapping Of Atrial Fibrillation |
US7359837B2 (en) | 2006-04-27 | 2008-04-15 | Medtronic, Inc. | Peak data retention of signal data in an implantable medical device |
US7764988B2 (en) | 2006-04-27 | 2010-07-27 | Medtronic, Inc. | Flexible memory management scheme for loop recording in an implantable device |
EP2083910B1 (en) | 2006-11-13 | 2019-08-14 | Washington University of St. Louis | Cardiac pacing using the inferior nodal extension |
US8738131B2 (en) | 2007-03-20 | 2014-05-27 | Medtronic, Inc. | Mechanical ventricular pacing capture detection for a post extrasystolic potentiation (PESP) pacing therapy using at least one lead-based accelerometer |
US8209033B2 (en) | 2007-05-14 | 2012-06-26 | Cardiac Pacemakers, Inc. | Method and apparatus for regulating blood volume using volume receptor stimulation |
WO2009006327A1 (en) | 2007-06-29 | 2009-01-08 | Action Medical, Inc. | Systems, devices and methods for monitoring efficiency of pacing |
JP2010532231A (en) | 2007-06-29 | 2010-10-07 | アクション メディカル インコーポレイテッド | Cardiac rhythm management method, management apparatus, and management system using electrode configuration |
JP5588340B2 (en) | 2007-06-29 | 2014-09-10 | カーディアック ペースメイカーズ, インコーポレイテッド | Method, apparatus and system for management of cardiac rhythm using electrode configuration |
WO2009006325A1 (en) | 2007-06-29 | 2009-01-08 | Action Medical, Inc. | Devices and methods for steering electrical stimulation in cardiac rhythm management |
WO2009006331A1 (en) | 2007-06-29 | 2009-01-08 | Action Medical, Inc. | Endocardial pacing devices and methods useful for resynchronization and defibrillation |
US7978062B2 (en) | 2007-08-31 | 2011-07-12 | Cardiac Pacemakers, Inc. | Medical data transport over wireless life critical network |
US9186089B2 (en) | 2007-09-14 | 2015-11-17 | Medtronic Monitoring, Inc. | Injectable physiological monitoring system |
US8145306B2 (en) * | 2007-10-15 | 2012-03-27 | Lessmeier Timothy J | Method for optimizing CRT therapy |
EP2224996B1 (en) | 2007-12-18 | 2014-05-07 | St. Jude Medical AB | Medical device for stimulation of his bundle |
JP5154692B2 (en) | 2008-04-15 | 2013-02-27 | カーディアック ペースメイカーズ, インコーポレイテッド | His bundle stimulation system |
US20100042176A1 (en) * | 2008-08-12 | 2010-02-18 | Pacesetter, Inc. | Temporal-based cardiac capture threshold detection |
WO2010071849A2 (en) | 2008-12-19 | 2010-06-24 | Action Medical, Inc. | Devices, methods, and systems including cardiac pacing |
US8565880B2 (en) | 2010-04-27 | 2013-10-22 | Cardiac Pacemakers, Inc. | His-bundle capture verification and monitoring |
WO2012005988A2 (en) | 2010-06-29 | 2012-01-12 | Sweeney Robert J | Cardiac contraction detection using information indicative of lead motion |
JP5501211B2 (en) | 2010-12-17 | 2014-05-21 | 日本ダイスチール株式会社 | Corrugated cardboard box and its die |
WO2012125273A2 (en) | 2011-03-14 | 2012-09-20 | Cardiac Pacemakers, Inc. | His capture verification using electro-mechanical delay |
-
2004
- 2004-12-20 AR ARP040104782A patent/AR047851A1/en unknown
-
2005
- 2005-12-13 JP JP2007548289A patent/JP5307401B2/en not_active Expired - Fee Related
- 2005-12-13 AU AU2005319498A patent/AU2005319498B2/en not_active Ceased
- 2005-12-13 CA CA002591121A patent/CA2591121A1/en not_active Abandoned
- 2005-12-13 US US11/300,611 patent/US7512440B2/en not_active Expired - Fee Related
- 2005-12-13 US US11/300,242 patent/US8346358B2/en not_active Expired - Fee Related
- 2005-12-13 WO PCT/US2005/045044 patent/WO2006068880A1/en active Application Filing
- 2005-12-13 EP EP05849548.2A patent/EP1830920B1/en not_active Not-in-force
-
2008
- 2008-10-10 US US12/249,479 patent/US8437848B2/en not_active Expired - Fee Related
- 2008-10-10 US US12/249,454 patent/US8428715B2/en not_active Expired - Fee Related
-
2009
- 2009-03-27 US US12/412,608 patent/US8285376B2/en not_active Expired - Fee Related
-
2012
- 2012-10-04 US US13/645,464 patent/US8838238B2/en not_active Expired - Fee Related
-
2013
- 2013-02-04 JP JP2013019149A patent/JP5744079B2/en not_active Expired - Fee Related
- 2013-05-02 US US13/875,681 patent/US8812106B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2005319498B2 (en) | 2011-04-07 |
WO2006068880A1 (en) | 2006-06-29 |
EP1830920A1 (en) | 2007-09-12 |
US20060142812A1 (en) | 2006-06-29 |
US7512440B2 (en) | 2009-03-31 |
EP1830920B1 (en) | 2013-10-09 |
EP1830920A4 (en) | 2008-04-02 |
US20090187226A1 (en) | 2009-07-23 |
US8346358B2 (en) | 2013-01-01 |
JP5307401B2 (en) | 2013-10-02 |
US20060136001A1 (en) | 2006-06-22 |
US20090093861A1 (en) | 2009-04-09 |
US8812106B2 (en) | 2014-08-19 |
AR047851A1 (en) | 2006-03-01 |
US8437848B2 (en) | 2013-05-07 |
JP2013121524A (en) | 2013-06-20 |
US20130096638A1 (en) | 2013-04-18 |
AU2005319498A1 (en) | 2006-06-29 |
US8838238B2 (en) | 2014-09-16 |
US8428715B2 (en) | 2013-04-23 |
US8285376B2 (en) | 2012-10-09 |
JP2008523950A (en) | 2008-07-10 |
US20090093859A1 (en) | 2009-04-09 |
US20130261690A1 (en) | 2013-10-03 |
JP5744079B2 (en) | 2015-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005319498B2 (en) | Ventricular pacing | |
US9008768B2 (en) | Methods, devices and systems for cardiac rhythm management using an electrode arrangement | |
US9031648B2 (en) | Endocardial pacing devices and methods useful for resynchronization and defibrillation | |
US8934969B2 (en) | Systems, devices and methods for monitoring efficiency of pacing | |
US8050756B2 (en) | Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management | |
EP2164560B1 (en) | Systems for cardiac rhythm management using an electrode arrangement | |
US8880169B2 (en) | Endocardial pacing relating to conduction abnormalities | |
US8825159B2 (en) | Devices and methods for steering electrical stimulation in cardiac rhythm management | |
WO2009006331A1 (en) | Endocardial pacing devices and methods useful for resynchronization and defibrillation | |
AU2008269934A1 (en) | Endocardial pacing relating to conduction abnormalities | |
WO2009006325A1 (en) | Devices and methods for steering electrical stimulation in cardiac rhythm management | |
WO2009006329A1 (en) | Circuit-based devices and methods for pulse control of endocardial pacing in cardiac rhythm management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |